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Introdução: A deficiência de ferro é um dos problemas nutricionais mais 
comuns no Mundo. Ao longo dos anos, o ferro intravenoso tem-se tornado o 
tratamento de eleição para a recuperação dos níveis de ferro e para 
estimular a eritropoiese em casos de deficiência de ferro severa. Os 
produtos comercialmente disponíveis partilham a mesma composição e 
estrutura no núcleo de ferro mas diferem na composição da cobertura 
carbohidratada e nas suas propriedades físicas (tamanho da nanopartícula, 
aglomeração) e químicas (comportamento em condições de dissolução, 
valência do ferro do núcleo), o que confere diferenças substanciais no 
comportamento farmacológico, e fundamentalmente na  sua eficácia e 
segurança. Contudo, esta relação não esta bem compreendida. 
Objectivo: Caracterização das propriedades físico-químicas dos quatro 
produtos de ferro intravenoso disponíveis no Reino Unido (Cosmofer ®, 
Venofer®, Ferinject® e Monofer®) e estabelecer uma relação entre essas 
propriedades e a sua eficácia e segurança. 
Métodos: O perfil de dissolução de cada produto foi determinado por um 
ensaio de dissolução lisosómica que foi desenvolvida para simular a 
dissolução lisosómica de ferro nanoparticulado intravenoso. O estudo da 
aglomeração das nanopartículas foi determinado por ‘particle sizing’ e por 
‘zeta potential’ em soluções que simularam as condições no soro. A fase 
mineral foi determinada por XRD e a valência do ferro do Venofer® foi 
estudada por voltametria linear.  
Resultados e discussão: Todos os produtos apresentaram sinais de 
aglomeração em condições fisiológicas, mas, entre eles, o Venofer 
apresentou a mais forte evidência de aglomeração, tanto em soro bovino 
fetal como em solução de cálcio e fosfato. Venofer exibiu, igualmente, a 
maior labilidade de ferro, enquanto que o Ferinject® revelou o 
comportamento menos lábil. O Ferinject® foi o único material a demonstrar 
carga positiva na sua superfície em suspensão aquosa, e o único que 
apresentou akaganeite como sendo a fase mineral presente no núcleo de 
ferro enquanto que o Cosmofer e o Monofer demostraram um perfil mais 
amorfo. Com a voltametria linear, um conteúdo ferroso maior do que o 
férrico foi inicialmente detectado no Venofer mas após a correcção da 
deposição da espécie ferrosa na superfície do eléctrodo, a espécie férrica foi 
a única a ser detectada.  
Conclusão: A metodologia estudada permitiu o estudo dos diferentes 
comportamentos dos produtos estudados em termos de labilidade de ferro, 
da relação entre a diminuição do tamanho da partícula e do aumento da 
amorficidade do núcleo com a facilidade e rapidez de disponibilização de 
ferro e com a consequente maior incidência de reacções anafilactóides 
após administração. Cargas positivas na superfície das nanopartículas 
poderão incrementar a afinidade com o fosfato sanguíneo, o que justifica 
os vários relatos de hipofosfatemia associado à administração de Ferinject. 
As fortes evidências de aglomeração verificadas com o Venofer aliadas à 
sua baixa robustez comprovam a sua formulação de ‘iron sucrose’ como a 
mais preocupante do ponto de vista da segurança. Apesar dos resultados 
não tao clarificadores quanto à valência do ferro no Venofer, a voltametria 
linear tem potencial para poder estudar a dissolução das nanopartículas de 
uma forma mais progressiva e com menos variabilidade. 
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Introduction: Iron deficiency is one of the most common nutritional 
deficiencies worldwide. Over the years, intravenous iron has become the 
preferred iron repletion and erythropoiesis treatment to severe iron 
deficiency. The intravenous iron products available commercially share the 
same core chemistry but differ in the composition of the carbohydrate shell, 
as well as, in physical (particle size, agglomeration) and chemical 
(dissolution performance, iron valence of the core) properties, which makes 
them vary substantially in pharmacological behavior, and ultimately, in the 
efficacy and safety profile. However, this relationship is not well 
understood. 
Aim: Perform a physicochemical characterization of the four IV iron 
products available in the UK (Cosmofer ®, Venofer®, Ferinject® and 
Monofer®) and establish a relationship between these properties and their 
efficacy and safety. 
Methods: The dissolution performance of each IV iron material was 
determined by a lysosomal dissolution assay which was developed to 
mimic the lysosomal dissolution of nanoparticulated IV iron. The 
nanoparticle agglomeration was determined by particle sizing assays in 
serum mimetic solutions, and by zeta potential. The mineral phase of the 
iron core of the nanoparticles was determined by XRD, and the 
ferrous/ferric presence in Venofer® was studied by linear voltammetry. 
Results and discussion: The four products revealed signs of nanoparticle 
agglomeration when in physiological conditions but, of these, Venofer 
exhibited the strongest evidence for agglomeration, in both fetal bovine 
serum and in a simple calcium and phosphate solution. Venofer also 
presented the highest iron lability whereas Ferinject had the least labile 
behavior. Ferinject was also the only material with positive surface charge 
when in a water suspension and with akaganeite as the mineral phase in 
the iron core, while Monofer and Cosmofer resembled a more 
amorphousness mineral phase. Indications of greater ferrous iron content 
than ferric were initially detected in Venofer but after the correction of the 
ferrous deposition in the electrode, the ferric specie became exclusive. 
Conclusion: The methodology developed allowed the study of the different 
behaviors of the four studied products in terms of iron lability, the 
relationship of the decrease of particle size and the increase of 
amorphousness with the ease and quickness of iron mobilization and 
bioavailability, and with the consequent higher incidence of anaphylactoid 
type reactions after administration. Positive surface charges might increase 
the affinity to serum phosphate, which justify the commonly reported 
hypophosphatemia associated to the administration of Ferinject. The strong 
evidences of agglomeration with Venofer and its poor robustness makes 
the iron sucrose material the most concerning in safety matters. Although 
the uncertain results regarding the iron valence of Venofer, linear 
voltammetry has the potential to assess the nanoparticulate dissolution 
more progressively and reliably.
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Abbreviations: 
 
AE = Adverse events 
DLS = Dynamic light scattering 
DME = Dropping mercury electrode 
DTS = Dispersion tecnhology software 
DMT-1 = Divalent metal transporter 1 
ESA = Erythropoiesis-stimulating agent 
FDA = Food and Drug Administration 
FGF-23 = Fibroblast growth factor 23 
GI = Gastrointestinal  
HDD-CKD = Haemodialysis dependent-chronic kidney disease 
HMW-ID = High molecular weight Iron dextran 
IRE/IRP = Iron response element/iron response protein 
ICDD = International Centre for Diffraction Data 
ICP-OES = Inductively Coupled Plasma - Optical Emission Spectrometer 
IV = Intravenous 
LIP = Labile iron pool 
LMW-ID = Low molecular weight Iron dextran 
NTBI = Non-transferrin bound iron 
PCS = Photon correlation spectroscopy  
QELS = Quasi-elastic light scattering 
RDE = Rotating disk electrode 
TIBC = Total iron binding capacity 
TDI = Total dose infusion 
Tf = Transferrin 
TfR1 = Transferrin receptor 1 
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1. Iron Homeostasis 
1.1 Iron distribution in Humans 
 The Human body contains approximately 3-5 g of iron (45-55 mg/kg of body 
weight in adult women and men, respectively) [1]. The vast majority of body iron (at least 
2.1 g in humans [2], 30 mg/kg [3]) is distributed in the haemoglobin of red blood cells and 
developing erythroid cells. The only other fraction of quantitative significance is storage 
iron in the liver, amounting to 15 mg/kg (~1g) in the adult male [4]. Significant amounts of 
iron are also present in macrophages (up to 600 mg) and in the myoglobin of muscles 
(∼300 mg) to a large extent within ferritin and its degradation product hemosiderin (Figure 
1) [2]. The remaining body iron is primarily localized in cytochromes and iron-containing 
enzymes [1].  
Since humans maintain a precise iron balance during adulthood, the normal loss of 
about 0.9 mg/day in the adult male is derived from the gastrointestinal (GI) tract (0.6 mg), 
from the desquamated epithelium of skin (0.2 mg) and from the urinary tract (0.1 mg). This 
iron is absorbed from a diet containing 10 to 20 mg of iron, so that the overall absorption 
of iron is at a level of about 6% [5]. Women during the childbearing years will lose about 
twice that amount due to menses and childbirth. The iron wasted in a specific volume of 
blood loss is greater in iron overload status, and it is reduced in cases of iron deficiency 
[4]. The body has no active means of excreting iron, and thus regulation of the absorption 
of dietary iron from the duodenum plays a critical role in iron homeostasis [5]. 
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Complex mechanisms have evolved to maintain extracellular iron concentrations in 
a relatively narrow range and to provide cells with adequate but not excessive iron for their 
metabolic needs. Blood concentration of iron is determined by iron absorption in 
duodenum, recycling of iron from aged erythrocytes by macrophages, iron storage by 
hepatocytes, iron utilization mainly by the bone marrow and iron losses by the faeces [3]. 
When one of these homeostatic mechanisms of iron is disrupted, the consequent iron 
imbalance could result in changed iron bioavailability and associated toxicology. 
 
1.2 Iron Deficiency 
Iron deficiency is a major problem health with 40% of the world’s population 
affected (1 to 2 billion people [6]) and it can be either functional or absolute. The first one 
is defined as a condition in which there is a failure to release iron rapidly enough to keep 
pace with the demands of the bone marrow for erythropoiesis, despite adequate total body 
Figure 1 - Iron distribution and loss in the Human [2]. 
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iron stores (ferritin with normal levels). This condition is commonly associated with 
erythropoiesis-stimulating agent (ESA) usage, because in this situation, iron uptake by 
erythroid cells is increased to meet the demand of increased red blood cells production, 
thereby preventing macrophages to release stores of iron fast enough to meet that demand. 
Another case might be associated with chronic inflammation where the iron transport 
across cell membranes is inhibited (e.g. by hepcidin in anaemia of chronic disease) which 
decreases accessibility of storage iron and G) absorption, leading to an increased frequency 
of iron-restricted erythropoiesis. Absolute iron deficiency occurs when total body iron 
stores become depleted, that is, the amount of stored iron is no longer adequate to meet the 
demands for erythropoiesis (e.g. chronic blood losses) [7, 8].  
Anaemia emerges in cases where severe iron deficiency impairs oxygen-carrying 
capacity of the red blood cells, and it is the most familiar clinical means by which iron 
deficiency is recognized as well as explains the common fatigue and pallor associated [7, 
8]. Iron deficiency may also reduce exercise performance, lead to an abnormal 
neurotransmitter function and result in altered immunological and inflammatory defences. 
In children, it can cause developmental delays and cognitive abnormalities, whereas in 
pregnant women, the likelihood of premature and low-birth-weight delivery is increased 
[9]. 
 
 
1.2.1 Causes 
Iron deficiency will result from any condition in which dietary iron intake does not 
meet the demands of the body and also when there is deprived iron absorption and on-
going blood losses. A list of the causes of iron deficiency is shown in Table 1 [1, 2]. 
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Table 1 – The four main causes of iron deficiency and the respective examples (adapted from [1, 2]). 
CAUSES  EXAMPLES 
Increased iron 
demands 
Pregnancy 
Infancy 
Patients treated with ESA 
Insufficient intake 
Chronic alcoholism 
Poor nutrition 
Inappropriate diet with deficit in iron and ascorbic acid 
Inadequate iron 
absorption 
Poor bioavailability 
High gastric pH  
Excess dietary tannin, phytates, or starch 
Competition from other metals (e.g. copper, lead) 
Loss of dysfunction or absorptive enterocytes 
Bowel resection 
Helycobacter pylori infection 
Inflammatory bowel disease, Chron’s disease,  Celiac disease,  ulcerative colitis 
Increased iron loss 
Gastrointestinal bleeding (ulcer,  varices, epistaxis) 
Genitourinary bleeding 
Pulmonary bleeding 
Other blood loss (surgery, blood donation, trauma, excessive phlebotomy, large vascular 
malformations, haemodialysis patients with chronic kidney disease) 
 
1.2.2 Assessment of Iron Deficiency  
Laboratory tests, such as haemoglobin concentration can be used to screen for iron 
deficiency, whereas serum ferritin concentration can be used to confirm iron deficiency. A 
low ferritin level is reliably indicative of depletion of iron stores (“absolute iron 
deficiency”) and normal or even high level may be associated with underlying iron 
deficiency in sick patients (“functional iron deficiency”). Other tests may be needed, such 
as haematocrit, erythrocyte zinc protoporphyrin concentration, transferrin (Tf) 
concentration, total iron binding-capacity capacity (TIBC) and serum iron concentration 
(Table 2) [10]. However, these parameters might be affected in other conditions (e.g. 
ferritin concentration elevated in patients with infectious, inflammatory, and neoplasic 
conditions). Bone marrow examination is a painful and invasive method but accurately 
shows the absence of stainable iron so it is the definitive method for diagnosing iron 
deficiency. Alternatively, if the cause is also identified, the clinical judgment in 
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combination with the measurement of haemoglobin and ferritin usually provides an 
accurate interpretation and leads to the necessary action [11, 12].  
 
 Body iron content 
Storage 
iron 
Transport  iron 
Functional 
iron 
Iron status 
Storage 
iron 
Transport  
iron 
Function
al iron 
Serum 
ferritin 
EP Tf conc/TIBC 
Tf 
saturation 
Serum 
iron 
Hb, Hct 
Iron overload ↑ ↑ N ↑ N ↓ ↑ ↑ N 
Normal N N N N N N N N N 
Iron depletion ↓ N N ↓ N N/↑ N/↓ N/↓ N 
Iron-deficient 
erythropoiesis 
↓ ↓ N ↓ ↑ ↑ ↓ ↓ N 
Iron deficiency 
anaemia 
↓ ↓ ↓ ↓ ↑ ↑ ↓ ↓ ↓ 
 
1.2.3 Treatment: Oral iron vs Intravenous iron 
 Safety 
Oral iron supplementation is a commonly used strategy to meet the increased 
requirements of risk groups, such as women of childbearing age. It has the advantage of 
being simple and cheap but it is limited by side effects (56%), poor adhesion to the 
intestinal walls, poor absorption and low efficacy [13]. Side effects of oral iron 
supplementation on GI tract may be troublesome, because replacement therapy takes a 
long time to replenish body iron stores and some patients have difficulty tolerating iron 
salts because these substances tend to cause GI distress and toxicity, forcing the 
discontinuation of treatment. Plus, liquid iron salt preparations, given to young children, 
may cause permanent staining of the teeth and are one of the causes of non-compliance. If 
provided in excess, oral iron may induce mucosal absorption block [14], peroxidative 
damage through production of ROS resulting in mucosal cell death, loss of functional 
integrity and decreased turnover of epithelial cells [9, 11]. 
Intravenous (IV) iron is the best means of guaranteeing delivery of readily available 
iron to the bone marrow and it is more efficacious than oral iron because, since the GI tract 
is bypassed, IV delivery promotes a more rapid and reliable repletion of iron stores with 
faster normalization of haemoglobin levels, it has better acceptance by the organism and 
less incidence and frequency of side effects. It has also the ability to keep pace with 
Table 2 - Parameters accepted to the assessment of iron deficiency. EP is the erythrocyte zinc protoporphyrin 
concentration, Tf is transferrin, TIBC is the total iron binding capacity, Hb refers to the haemoglobin concentration, 
Hct is the haematocrit and N means normal values (adapted from Trost et al, 2006 [10]). 
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continuous blood loss and sustain iron adequacy resulting in lower transfusion 
requirements and shorter length of hospital stay [15, 16]. However, IV iron requires great 
clinical supervision and there still remain concerns about iron overload, the acute safety 
profiles of the available IV products and the potential for long-term harm from repeated 
administration because all IV iron cause acute severe reactions [17]. Table 3 shows a 
practical example of the better safety profile of IV delivery in a study trial [18]. 
 
 
 When to use 
Because of its limitations, oral iron is administrated in non-urgent iron repletion 
where minor iron deficiency is noted in patients with other conditions that would not be 
compromised by the presence of iron deficiency [7].  
IV iron is indicated specially for treatment of severe iron deficiency where there is 
an exacerbated erythropoiesis request or a clinical need to deliver iron rapidly to replenish 
iron stores. This condition is associated with the following situations [7, 15]:  
Table 3 - List of adverse events occurred possibly or definitely related to ferric gluconate administrated in cancer 
patients with chemotherapy-related anemia and functional iron deficiency. FG stands for sodium ferric gluconate 
[18]. 
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 Malabsorption of iron e.g. Anaemia of chronic disease, inflammatory bowel disease) 
 On-going loss of blood, e.g. Haemodialysis patients with Dependent-Chronic kidney 
disease (HDD-CKD).  
 Increased iron demands (Obstetrics or ESA therapy patients). 
 Anaemia heart failure and ischemic heart disease.  
 Anaemia associated with poor iron absorption (i.e. anaemia of chronic disease, 
anaemia associated with cancer).  
Sometimes IV iron treatment is required even in mild iron deficiencies when poor 
absorption, intolerance and non-compliance to oral iron therapy occurs (Figure 2) [19]. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 - Flowchart for the use of IV  iron in confirmed iron deficiency anaemia, when 
oral iron cannot resolve the clinical problem [19]. 
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 Administration strategy 
An IV iron dose requires it to be diluted in 0.9% NaCl before administration by 
drip infusion or by bolus injection (Venofer® and Ferinject® can be injected undiluted). In 
case of haemodialysis patients, undiluted injection into the limb of the dialyser can be 
applied. The cumulative dose required for haemoglobin restoration and repletion of iron 
stores is calculated by the following Ganzoni formula:  
 
 
 
 
 
 
 
 
 
If the required dose exceeds the maximum dose permitted, whether half of the dose 
is administrated in consecutive days, or the maximum dose in given in the first infusion 
followed by the reminder in the second infusion. 
In general, all IV iron materials are contraindicated in cases of anaemia not 
attributable to iron deficiency, in iron overload, in disturbances of utilization of iron (e.g. 
haemosiderosis), history of hypersensitivity to parenteral iron preparations, as well as in 
patients with a history of asthma, allergic eczema or other atopic allergy [20].  
 
 
2. Intravenous iron materials 
 
All the current IV iron agents are colloids that consist of small spheroidal iron-
carbohydrate nanoparticles with an iron oxyhydroxide core surrounded by a carbohydrate 
shell that stabilizes the core, slows the release of iron from the core and maintains the 
resulting particles in a colloidal suspension (Figure 3) [21]. All the IV iron agents share the 
same core chemistry but differ from each other by the particle size and the identity of the 
surrounding carbohydrate [17, 22, 23]. 
 Iron replacement in patients with iron deficiency anaemia: 
Total iron deficit = Weight (kg) x (Target Hb – Actual Hb) (g/l) x 2.4 + Iron stores (mg) 
>35 kg Body Weight: Target Hb=150 g/L, iron stores=500 mg. 
  
 Iron replacement for blood loss (no need to replenish the iron stores): 
Total iron deficit = Weight (kg) x (Target Hb – Actual Hb) (g/l) x 2.4 
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Iron oxyhydroxide 
core (FeOOH) 
Carbohydrate shell 
 
 
 
 
 
 
 
 
 
 
2.1 Iron core 
Ferritin accommodates iron efficiently in an oxyhydroxide ferrihydrite-type solid 
form and releases it promptly, maintaining an intact structure during this reversible 
process. Therefore, the IV iron preparations were conceived to have an inorganic core 
similar to this protein so that its activity as a synthetic iron store in the organism would be 
ideally similar [24, 25]. The current nanoparticles cores have been identified as iron 
oxyhydroxide most consistent with a mineral phase of the akaganeite polymorph (β-
FeOOH) for all products except for Ferumoxytol, which is thought to have a magnetite and 
maghemite mixture [26, 27].  
 Akaganeite resembles the hollandite-like BaMn8O16-type crystal structure with a 
tetragonal or monoclinic unit cell and it contains “tunnel” shaped cavities occupied by 
chloride or hydrogen propagating in the c-axis by edge linkages between Fe octahedra. The 
chloride atoms present in this akaganeite crystal are essential to maintain a stabilized 
polynuclear ferric oxyhydroxide crystal cell structure, and their complete or partial 
removal after synthesis leaves channels in the structure that opens core access to ferric ions 
(Figure 4) [24, 28, 29]. 
Figure 3 – Schematic of an iron oxyhydroxide nanoparticle present in the 
intravenous preparations [21]. 
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The presence of octahedrally coordinated high spin ferric ions were identified 
coordinated with six oxygen atoms at a Fe–O distance of 1.95 Å, and at the location of a 
disordered shell of iron ions at a distance of about 3.05 Å. The iron oxyhydroxide 
crystallite dimensions estimated are generally about 1–5 nm in diameter and the 
dimensions of the core (which may be larger than the size of the crystalline portion) can 
range from 3 nm diameter spheres to 5 × 34 nm ellipsoidal particles [26]. In exception of 
the superparamagnetic Ferumoxytol, the low particle magnetic moments confer the IV iron 
materials very low magnetic response, consistent to the antiferromagnetic structure of 
akaganeite.[25]. 
Figure 4 - Akaganeite (β-FeOOH,Cl) structure [28]. 
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2.2 Carbohydrate shell 
Carbohydrates can be appropriate chelating agents for the stabilization of the iron 
core by slowing down the release of iron, avoiding the contact to the surrounding 
molecules and maintaining it as a colloidal suspension. Certain carbohydrates, such as 
sucrose, present multiple hydroxyl groups in a suitable array to chelate iron, although the 
binding is weak in neutral aqueous solution. Polymeric carbohydrates such as dextran are 
also used to stabilize nanoparticles because they present a large number of hydroxyl 
groups, which can cooperatively chelate the surface of iron oxyhydroxide nanoparticles. 
For a neutral carbohydrate, the chelation to iron is enhanced at high pH, because the 
hydroxyl groups may become deprotonated, thus acquiring a negative charge, and 
interacting more strongly with the cationic iron ion. At neutral pH, inherently anionic 
carbohydrates such as gluconate are more effective nanoparticle stabilizers. In these cases, 
a carboxyl group provides the negative charge over a broad pH range. Carboxylic chelation 
to iron can also drive the deprotonation of nearby hydroxyl groups, further enhancing the 
complex stability [26]. Each carbohydrate has a surface charge in result to the expose of 
these hydroxyl and carboxylic groups to the surrounding medium, which can affect 
nanoparticles biodistribution by limiting or enhancing interactions of nanoparticles with 
serum proteins, electrolytes, and non-targeted cells [30]. 
2.3 Mode of action 
After injection or infusion of the IV iron material, the distribution and uptake of 
nanoparticles by the macrophages depends largely on their physicochemical properties 
such as particle size and surface charge. Thus, when nanoparticles enter the bloodstream, 
they instantly encounter a complex environment of plasma proteins and phagocytic cells. 
Nanoparticles tend to adsorb to specific plasma proteins such as immunoglobulins, 
apolipoproteins, components of Complement System and clotting factors, necessary to 
mediate nanoparticle recognition and uptake by the macrophages (phagocytosis) [31, 32]. 
The following intracellular metabolism is yet to be fully understood but 
phagocytised iron oxide nanoparticles have been shown to be transferred from early to late 
endosomes (neutral pH) where they may fuse with more acidic lysosomes and become 
solubilized at lower pH environment, typical of the endolysosome (pH 4.5-5.5), with no 
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enzymatic involvement. The explanation of this hypothesis can be based on what happens 
in the normal iron metabolism in the cells. The structure of iron oxide nanoparticles is very 
similar to that of ferritin because ferritin has an iron oxide core consisted by ferric iron as a 
solid under physiological pH, coated by a shell. After degradation of ferritin by lysosomal 
proteases, its iron oxide will be exposed to the surroundings and dissolve. So, it is very 
likely that the safety of iron nanoparticles is due to degradation of the carbohydrate shell 
and the iron oxide core in lysosomes, where the iron oxide of the ferritin is degraded 
(Figure 5) [33, 34].  
 
 
Moreover, for the release of the free iron from the endolysosome, it should be noted 
that, in the cellular uptake of iron trough the TfR1 (Transferrin receptor 1) pathway, the 
transport of iron from the endosome into the cytoplasm involves binding of the iron to 
various low molecular-weight molecules or transmembrane proteins. Therefore, following 
the degradation of nanoparticles, it may be speculated that such endogenous Fe(III) 
chelating compounds facilitate the dissolution and the release of free iron to the Labile Iron 
Pool (LIP), where it is stored as ferritin/hemosiderin or transported, in lesser extent, out of 
the cell by ferroportin. Thus, the metabolism of the iron liberated from the core is most 
probably taken care by the intracellular system for normal iron metabolism [17, 33, 34]. 
Figure 5 – Processing of IV iron nanoparticles since the product is administrated till the nanoparticles 
reach the erythroid precursors in the bone marrow. 
Fe3+ 
Fe3
+ 
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The iron exported out of the cell is bound to transferrin and it is delivered to the 
transferrin receptor on the surface of erythroid precursors, supporting haemoglobin 
synthesis and maturation of red blood cell correcting the iron deficiency anaemia. The rate 
of transfer of iron from the macrophages into the circulation seems to depend mostly on 
the severity of iron deficiency and the rate of erythropoiesis. When the patient is severely 
iron deficient, incorporation of iron from IV iron agent into erythroid precursors occurs 
rapidly whilst in the absence of evidence of iron deficiency, donation of iron from the 
macrophage to red cells after IV iron administration is blunted, and in patients with cancer 
or inflammation, little or no erythroid iron uptake may occur. Although every IV iron 
materials follow this mode of action, there are observations of small fractions that likely 
bypass the intracellular steps and donate iron directly to transferrin in plasma, which, 
although not safe, gives a more rapid delivery of iron to the bone marrow [22, 23].       
2.4 Chemistry of IV agents & Pharmacologic outcomes 
Differences in core size, carbohydrate chemistry and the strength of the iron 
complex determine pharmacologic and pharmacokinetic differences, including clearance 
rate after IV administration, rate of release of iron from the ferric hydroxide, maximum 
tolerated dose and rate of infusion. 
 
2.4.1 Particle size 
Size is one of the key parameters in the protein adsorption to the nanoparticles in 
the plasma (opsonization) and, thus, in the circulation half-life of nanoparticles. When 
discussing size distribution of particles it is important to remember that it is the 
hydrodynamic diameter and not the diameter of the metal core that is most important for 
biodistribution and excretion [33]. Sizes bigger than 30nm suffer a main uptake by the 
macrophages in the liver, spleen and some uptake by the bone marrow. Nanoparticles with 
a hydrodynamic radius smaller than 5 nm or polymer nanoparticles with a molecular 
weight less than 50kDa have higher renal clearance [31, 33].  
The relative diameters (Table 4) of the iron nanoparticles follow the sequence 
observed for overall molecular weight (High Molecular Weight-Iron Dextran (HMW-ID) > 
Ferumoxytol > Iron Carboxymaltose > Low Molecular Weight-Iron Dextran (LMW-ID) > 
Iron isomaltoside > ferric gluconate ≈ iron sucrose) and further establishes that the relative 
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diameters of the mineral cores follow the same sequence as those of the complete 
nanoparticle. This has important implications for core surface area available for bioactive 
iron release [22, 35]. Likewise, the core radius gives a potential explanation to the rate of 
release of iron and to the magnitude of the labile iron effect as well as to the dose and rate 
of infusion. Since all IV iron materials share the same core crystallinity, the rate of iron 
release per unit surface area would be most likely similar among materials (differing only 
by the strength of the carbohydrate ligand-core iron bond). However, for the same total 
amount of core iron, the surface area available for iron release increases dramatically as 
core radius decreases because surface area is = 4πr2, and volume is = 4/3πr3, then the ratio 
of surface area to volume is = 3r
_1
. In short, a collection of many small spheres exposes a 
greater total surface area than does a collection of an equal mass of fewer, larger spheres 
(Figure 6) [22, 35, 36].  
 
 
 
 
 
 
 
 
 
 
 
So, the smaller the particle size, the bigger is the surface area and the bigger is the 
evidence of labile weakly bound iron as well as more rapid is the iron release. The fraction 
of labile iron decreases in the order of Iron Sucrose ≈ Iron Gluconate >> Iron Dextran > 
Iron isomaltoside 1000 ≈ Ferumoxytol > Iron Carboxymaltose. As the labile iron can cause 
free iron like reactions, the size of the labile iron fraction may be dose limiting, and, if so, 
then the maximum tolerated dose and rate of administration would be inversely related to 
labile iron fraction and, consequently, to the particle size, and would follow the sequence 
LMW-ID ≈ Iron isomaltoside > Iron carboxymaltose > Ferumoxytol > Iron sucrose > Ferric 
gluconate [22, 35].  
Figure 6 - A simple comparison of surface area between a large 
iron core and the same mass of smaller iron cores [36]. 
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 Accordingly, the rate of uptake of IV iron into the macrophages depends also on 
the particle size because, in general, the smaller the size, the more rapid is the clearance of 
the nanoparticles from plasma after an IV dose as well as the consequent saturation of Tf, 
which reflects in an inferior half-life too. A long serum half-life will influence the time for 
continued iron donation and the peak drug concentration achieved, which will result in 
serious implications after administration of higher than approved doses [22, 35, 37]. It has 
been suggested that given the same iron loading dose, the rate of metabolism and 
utilization of IV iron may be lower for agents with higher particle sizes. Prolonged 
exposure of a product to plasma leads to greater degrees of iron donation. Rapid cellular 
uptake, characteristic of the smaller nanoparticles, may limit late iron donation in plasma 
only to augment the intracellular manifestations of labile iron [37]. Although the precise 
cellular events occurring after iron-carbohydrate compounds are taken up by macrophages 
have not been elucidated, the observation that plasma clearance of iron dextran follows 
first-order kinetics after IV doses up to 500 mg but zero-order kinetics at higher doses 
suggests that the clearance mechanism is saturable [22]. 
As previously mentioned, iron agents can also donate iron directly to Tf although in 
a very low extent, and it is suggested by previous in vitro work that iron donation to Tf is 
inversely related to the particle size and directly related to concentration and circulation 
time [38]. 
The dose must also be thought accordingly to the volume of distribution of the IV 
iron in use because when iron is injected intravenously, it is distributed in the plasma 
space, so that the calculated initial volume of distribution roughly approximates plasma 
volume. The reported finding that ferric gluconate achieves a peak plasma concentration 
only half of that expected, prompts the conclusion that the agent is distributed in a volume 
equal to twice the plasma volume. The resulting conclusion that 50% of the iron in ferric 
gluconate dissociates immediately from the compound and exits the intravascular space 
seems quantitatively implausible. Qualitatively, however, the pharmacokinetics of ferric 
gluconate support that the large labile iron fraction in this agent may be clinically 
important early, after IV administration [35, 37].  
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2.4.2  Carbohydrate shell chemistry 
 Coating carbohydrates limit or delay water access to the core conferring 
significantly longer degradation rates of the nanoparticles reflected by the increase of the 
half-life of these particles [39]. Hydrophobic and high surface charged (either negative or 
positive) nanoparticles have short circulation times due to adsorption of plasma proteins 
which can lead to recognition by the macrophages followed by removal from circulation. 
Surface charge is reported to influence the tolerability and bioavailability of iron hydroxide 
nanoparticles in endocytic membranes, in particular by enhancing adsorption and uptake, 
probably via electrostatic interaction [30, 40]. As dextran is a neutral hydrophilic polymer 
whereas sucrose and gluconic acid are negatively charged, this can also explain the lower 
half-life and the faster uptake of Venofer® (iron sucrose) and Ferrlecit® (Ferric 
Gluconate) than dextran-like Cosmofer® [40, 41]. 
 
2.5 Current IV iron materials 
Currently seven parenteral iron preparations are available in the market (Table 4). 
The first generation preparations were the first ones to be manufactured and are 
characterized by the dextran nature of the carbohydrate shell, its robustness, the associated 
high incidence of anaphylaxis and the subsequent slow and high dose administration. The 
second generation are the smallest iron nanoparticulated materials with high iron lability 
associated anaphylactoid-type reactions and, thus, with low and slow administrations. The 
third generation are the newest products, which aims to overcome some of the issues 
associated with the previous IV irons allowing the administration of higher and faster 
doses. 
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 The products characterized in this project consisted in Cosmofer® (1
st
 generation), 
Venofer® (2
nd
 generation), Ferinject® and Monofer® (3
rd
 generation).  
 
2.5.1 Iron Dextran 
Dextran is a polysaccharide polymer composed exclusively of α-D-glucopyranosyl 
units with varying degrees of chain length and branching (Figure 7).  An important factor 
in the choice of dextran appears to be the favourable size of dextran chains, which enables 
optimum polar interactions (mainly chelation and hydrogen bridges between the hydroxyl 
dextran groups and the oxide surface of the core) with iron oxide surfaces. Although single 
hydrogen bridges are relatively weak, the total bonding energy of these hydrogen bonds 
over the length of a polysaccharide molecule can be very high because of the large number 
of hydroxyl groups per molecule. The cores of both high and low molecular weight dextran 
materials resemble akaganeite [42]. 
 
Active 
Pharmaceutical 
Ingredient (API) 
Trade name Manufacturer 
Launch 
year 
Availability 
1st 
generation 
Low Molecular Iron 
Dextran 
Cosmofer® Pharmacosmos 1991 Europe 
INFeD® 
Watson 
Pharmaceuticals, Inc 
1991 USA 
High Molecular Iron 
Dextran 
Dexferrum® American Regent, Inc 1996 USA 
2nd 
generation 
Ferric Gluconate Ferrlecit® Sanofi-Aventis  1999 
Europe (not 
in UK) and 
USA  
Iron Sucrose  Venofer® 
American Regent, Inc 2000 USA 
Vifor Pharma 2000 Europe 
3rd 
generation 
Ferric 
carboxymaltose 
Ferinject® Vifor Pharma 2008 Europe 
Ferumoxytol Feraheme® 
AMAG 
Pharmaceuticals 
2009 USA 
Iron isomaltoside 
1000 
Monofer® Pharmacosmos 2010 Europe 
Table 4 – The eight current IV iron materials and the respective classification, trade name, launch year and availability 
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 High molecular weight iron dextran (Dexferrum®) 
Iron dextran was the first IV iron preparation used in haemodialysis patients [43]. 
HMW-ID became available for IV infusion in the United States after 1971 as “Imferon®” 
(Fisons pharmaceuticals). This material bypassed the prohibitive toxic reactions associated 
to the lack of carbohydrate shell of the previous parenteral iron materials (i.e. ferric 
hydroxide and iron saccharide) because it introduced dextran as a strong and robust iron 
coating for the iron oxide core, reducing the release of free iron during infusion, which 
accounted for a lower incidence of adverse reactions and more rapid hematologic 
responses. Unfortunately, dextran can easily develop antidextran antibodies, in a way that 
the administration of HMW-ID became associated of severe allergic reactions (even in the 
test doses [44]) and deaths due to anaphylaxis. Thus, it was withdrawn from the market, 
until the approval of the next HMW-ID (Dexferrum®) version in 1996 [45, 46]. 
The currently available Dexferrum® contain spheroid nanoparticles of 265 kDa and 
a particle size of 30±10 nm [22]. The material is a sterile non-pyrogenic solution that 
contains 50mg of elemental iron per mL of solution, a pH of 4.5-7.0, and does not contain 
preservatives.  The administration of the undiluted solution must be done slowly, at a rate 
no greater than 1 mL/min (50 mg/min) and should not exceed 2 mL (100 mg) daily and a 
Figure 7 - Structure of the dextran polysaccharide which is used in the coating of the 
nanoparticles of Dexferrum® and Cosmofer® [36]. 
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test dose is required because of the dextran nature. After injection, circulating iron dextran 
follows the macrophage fate described above, with negligible amounts of iron being lost 
via urinary or fecal way. Studies involving intravenously administered iron dextran to iron 
deficient subjects who had coexisting end-stage renal disease and other clinical problems, 
have yielded an average half-life value of 58.9 hours [47]. 
 
 Low molecular weight iron dextran (Cosmofer®) 
After realization that the higher molecular weight dextran was the main culprit for 
allergic reactions, the iron dextran re-emerged in the market in 1991 as LMW-ID 
(Cosmofer®) which had less variability among the side chains and resulted in 8.1 times 
fewer adverse events (AEs) likely to occur in comparison to HMW-ID [45]. Besides the 
advantage of low rate of adverse effects, this material can also be administered in a total 
dose infusion (TDI) because iron coated with dextran has the advantage of a longer half-
life and slow sustained release of elemental free iron into the circulation. This feature 
allows the administration of a total dose to replenish iron stores at one infusion in a cost-
saving way. LMW-ID has been shown to have a comparable safety profile with a number 
of other non-dextran parenteral iron materials, including iron sucrose and sodium ferric 
gluconate. In fact, it has been showed that the TDI of LMW-ID was also found to be 
equally safe compared with infusion of high-dose iron sucrose [46]. 
Cosmofer® is a material with a molecular weight of 90-165 kDa [17, 48], a 4.4-5.6 
nm core and an average hydrodynamic diameter of about 12.2 nm [27]. It is negatively 
charged and has a stock pH of 5.2-6.5. The vial has a 50 mg/mL of iron and can be 
administrate, as a conventional series of small IV doses or as a TDI with up to 20 mg/kg of 
body weight administered over 4-6 hours in one single infusion. Although the plasma half-
life is 5 hours for circulating iron and 20 hours for total iron (bound and circulating), an 
increased haematopoiesis can be observed for the following 6-8 weeks. Due to the size of 
the complex, CosmoFer® is not eliminated via the kidneys and there is minimal removal 
of iron dextran during haemodialysis which do not warrant a change in the dosage schedule 
[49]. 
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2.5.2 Ferric Gluconate (Ferrlecit®) 
Ferric gluconate rapidly replaced iron dextran as the preferred IV iron preparation. 
It contains the same iron hydroxide core as iron dextran, but utilizes sucrose and gluconate 
to stabilize and solubilize the compound [50]. 
This macromolecular complex (Figure 8) has an apparent molecular weight of 164-
444 kDa, a mineral sphere core with a diameter of 2-4.1 nm, an average hydrodynamic 
diameter of about 8.6-10 nm [27]. 
The manufacturing of the Ferric Gluconate complex is made through the standard 
procedure, previously described, to originate the iron (III) oxyhydroxide, followed by the 
reaction of the formed ferric hydroxide with sodium gluconate in a sucrose solution to 
obtain a crude sodium ferric gluconate complex Na[Fe2O3(C6H11O7)(C12H22O11)5]n=200, 
which is soluble in a mildly alkaline aqueous sucrose solution [51].  
 
 
 
 
  
 
 
Spectroscopic data and elemental analysis suggested that the core resembles 
akaganeite and it contains 102 repeating Fe(III)OOH centres bound in pseudo-octahedral 
coordination to 13 gluconate and five loosely associated sucrose molecules [26, 27]. The 
carboxylate groups in gluconate serve as the bridging group between iron centres with 
coordinated sucrose molecules bound both directly and weekly to each Fe(III) (Figure 8) 
[51].  
Ferrlecit® is supplied in a single ampule or vial containing 62.5 mg of elemental 
iron in 5 mL (12.5mg/mL) and 20%(w/v) of glucose (195mg/mL). It contains 
benzylalcohol 0.9% (w/v) (9mg/mL) as preservative. It is negatively charged and it has a 
pH of 7.7-9.7. The maximum single dose is 10mL of 125mg of iron given over 1h per 
haemodialysis [52].  
The pharmacokinetics in iron-deficient adults who are not on dialysis was 
described by Seligman et al [53]. In that study, it was shown that ferric gluconate-derived 
Figure 8 - The proposed structure of Sodium Ferric Gluconate (Ferrlecit®) [51]. 
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iron was rapidly transferred to Tf, after digestion in the macrophage. Later, Warady et al 
studies on children in haemodialysis were able to define a linear pharmacokinetics where 
the [Fe]total and the [ferric gluconate-Fe]serum increased in a dose-dependent manner that 
was approximately proportional to the administrated dose, whereas Kel, clearance, half-life 
and distribution volume were similarly irrespective of dosage. In contrast, there was a 
slower and less prominent rise in the concentration of Tf bound iron. This delayed rise was 
greater after the higher dosage of ferric gluconate, which is reflective of the iron movement 
in the body whereby ferric gluconate first delivers iron to the macrophage as opposed to 
direct transfer to Tf [54]. 
The product does not have dextran content, so it may not share the antigenicity of the 
iron dextran materials. Therefore no test dose is required. However, it is a much smaller 
complex than iron dextran and, because of the weakness of the iron complex, it suffers a 
more rapid dissociation which may enhance the risk of acute toxicity due to a bigger 
percentage of labile (weakly bound) iron. With fast degradation kinetics and higher 
percentage of direct release to plasma proteins (apotransferrin, apoferritin, and others), the 
potential for acute adverse reactions related to labile iron release after IV injection is 
higher with iron gluconate compared to the other available IV iron preparations and it is 
caused by oversaturation of the Tf binding capacity [55]. 
2.5.3 Iron Sucrose (Venofer®) 
Iron sucrose, also known as iron saccharate, is a complex of polynuclear iron (III)-
hydroxide in sucrose. Iron sucrose has a molecular weight of approximately 34–60 kDa, a 
particle size of 7-8.3 nm and the proposed structural formula: Na2[Fe5O8(OH)·3(H2O)]n × 
m(C12H22O11) [43], where n stands for the degree of polymerization and m is the number of 
sucrose molecules surrounding the iron core [56]. The spherical core has a proposed 
structure close to 2-line ferrihydrite, possibly mixed with layers of akaganeite, it has an 
average diameter of 3±2 nm and it contains about 416 FeOOH surrounded by roughly 24 
sucroses [26, 27]. Each mL of the vial contains 20mg of elemental iron and 30% sucrose 
(w/v) (300 mg/mL). It has a pH of 10.5-11.1 and an osmolarity of 1250 mOsmol/L. It 
contains no preservatives. The administration can occur by slow injection or infusion with 
a maximum single dose of 200 mg during 2-5 minutes and the usual total iron repletion 
treatment course of Venofer® is 1000 mg. It requires a test dose only in Europe [57]. 
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In healthy adults treated with IV doses of Venofer®, the iron component exhibits 
first-order kinetics. Its half-life is 5-6 h, and after a single dose of 100 mg, iron is uptaken 
rapidly in bone marrow, liver, and spleen, followed by occurrence of injected iron in 
circulating erythrocytes. The amount of iron transported by Tf, calculated using the 
Michaelis-Menten model for a single dose containing 100 mg of iron, is around 30 mg 
Fe
3+
/24 h and the total erythrocyte uptake accounts for 68% to 97% of injected iron within 
2–4 weeks [55, 67]. The total clearance is 1.2 L/h, and the volume of distribution is the 
central compartment is 3.2 L. The sucrose component and 5% of the total iron are 
eliminated mainly by urinary excretion [67]. 
2.5.4 Ferumoxytol (Feraheme®) 
Ferumoxytol started a new generation of robust and strong parenteral iron 
preparations (with ferric carboxymaltose and iron isomaltoside) without the 
disadvantageous characteristics associated with iron dextran (anaphylaxis) and with iron 
sucrose and ferric gluconate (high iron lability, ergo dosage limitations, and the long 
duration of administration). This offers higher single-dose options, no test dose required 
and all can be rapidly administrated [55]. 
Ferumoxytol was approved by the Food and Drug Administration (FDA) for iron 
replacement in patients with iron deficiency anaemia and CKD. Originally developed as a 
magnetic resonance imaging (MRI) contrast agent due to its magnetic properties [58], 
ferumoxytol consists in superparamagnetic iron oxide nanoparticles with a polyglucose 
sorbitol carboxy-methylether coating. It has a molecular weight of 731-750 kDa and a 
colloidal particle diameter of 23.6-30 nm [17, 27]. The available material is negatively 
charged, it has an osmolarity of 270-330 mOsm/kg, it does not contain preservatives, and it 
is a 6-8 pH sterile liquid injection containing 30 mg of elemental iron/mL, with mannitol 
44 mg/mL for isotonicity [59]. Ferumoxytol core structure resembles magnetite and 
maghemite with a diameter of 6.2 ±1.4 nm [27].  
Ultrafiltration studies show that the labile iron and free iron content in ferumoxytol 
injection is the lowest of the available iron injection preparations. Similarly, the use of a 
bleomycin-detectable iron assay and ex vivo/in vivo rat experiments measuring free iron 
release of the various injectable iron products could found the lowest amount of free iron 
resulting from ferumoxytol. This property explains why ferumoxytol can be safely and 
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rapidly administrated intravenously in relatively high doses with a maximum single dose of 
510 mg administrated in a 17 seconds single push as 1mL (30 mg/s) [60, 61]. Also, in a 
randomized trial of patients with CKD stages one to five, two 510 mg injections of 
ferumoxytol administered within a week increased haemoglobin levels significantly higher 
than in patients receiving oral iron, including those with and without simultaneous ESA 
therapy [62] . Meanwhile, just one serious AE (anaphylaxis) was observed in a treatment 
arm in a patient with history of multiple drug allergies, but the patient recovered. The 
authors concluded that ferumoxytol is well tolerated with decreased immunological 
allergic reactions, low in other acute AEs and it has a safety profile similar to a placebo 
saline solution in anaemic patients with CKD  [63]. For this reason it does not require test 
doses.  
Regarding the pharmacokinetics, intravenously injected Fe-labelled ferumoxytol 
was noted to be quickly incorporated into red blood cells in non-anaemic rats. It was 
detected in red blood cells within 24 hours after injection, and over half of the dose was 
detected in red blood cells 2-4 weeks after injection contrasting with the iron from sodium 
ferric gluconate and iron sucrose that, in severe iron deficiency, it is incorporated into red 
blood cell precursors and is relatively complete 2-4 weeks after administration. It was 
suggested that the volume of distribution (Vd) of ferumoxytol was consistent with plasma 
volume and that other pharmacokinetic parameters are dose dependent, such as an 
increasing half-life, mean maximum observed plasma concentration (Cmax) and a 
decreasing total body clearance as the dose increases. The estimated values of clearance 
and Vd following two 510 mg doses of ferumoxytol administered intravenously within 24 
hours were 69.1 mL/h and 3.16 L, respectively. The Cmax and time of maximum 
concentration (tmax) were 206 mcg/mL and 0.32 h, respectively [60, 64].  
2.5.5 Ferric carboxymaltose (Ferinject®) 
Ferric carboxymaltose is a stable dextran-free iron complex with low immunogenic 
potential, and it is administrated at nearly neutral pH (5.0–7.0) and physiological 
osmolarity. The nanoparticle consists in a polynuclear iron(III)-oxyhydroxide core, 
structurally in accordance with akaganeite, stabilised with a branched carboxymaltose 
polysaccharide shell (Figure 9) giving an average hydrodynamic diameter of about 23.1 
nm and a molecular weight around 150-233.1 kDa [17, 27, 65].  
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Figure 9 - Model for the proposed molecular structure of ferric carboxymaltose [65]. 
 
The robust structure similar to Ferumoxytol makes it possible to administer higher 
single doses over shorter time periods [61] providing cost saving potential. The preparation 
has 50 mg of elemental iron per mL of solution allowing doses of 15 mg/kg of body weight 
(up to a maximum dose of 1000 mg in 15 minutes, per week) to be delivered in a single 
administration. The other ingredients are aluminium (up to 75 µg/mL), sodium hydroxide 
and hydrochloric acid for pH adjustment, and water for injection, which may be of concern 
in dialysis patients and those on sodium-restricted diets [15].  
After its administration, the pharmacokinetic characteristics of Ferinject® are 
similar but not identical to iron dextran. The distribution volume of both preparations 
corresponds nearly to that of plasma, but the half-life is approximately 7-12h for 
Ferinject® as compared to 25-30 h for LMW-ID. It seems that Ferinject® is degraded 
quicker than iron dextran because the plasma it is suggested that the carbohydrate part of 
Ferinject® is degraded to simple sugars by the enzyme α-amylase in a faster rate than 
dextran, so maximum concentrations of iron from Ferinject® in plasma are reached in 
approximately one hour followed by the rapid capture by the macrophages. As a result, the 
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utilization of iron for erythrocytes increases rapidly up to 6 to 9 days, continuing to 
increase in a much lower rate. Patients with iron deficiency anaemia showed erythrocyte 
iron utilization over 90% of the material administered. Different studies on postpartum 
anaemia, uterine bleeding and in patients doing haemodialysis have confirmed the efficacy 
and safety of Ferinject®, as the haemoglobin rates quickly increase and the biological 
stores of iron are quickly refilled with few secondary effects [55, 66]. 
2.5.6 Iron isomaltoside (Monofer®) 
The newest IV iron agent Iron isomaltoside 1000 was introduced in Europe in 2010 
as Monofer®, with iron being available in a non-ionic water-soluble form in an aqueous 
solution with pH between 5.0 and 7.0 with a concentration of 100 mg of elemental iron per 
mL of solution (vial) [67].  
The average hydrodynamic diameter of the nanoparticle is about 9.9 nm (150 kDa 
[17]). The iron oxyhydroxide core seems to consist of a “mixed layer” similar to 
akaganeite whereas the carbohydrate is made of spherical shaped particles with a similar 
structure to dextran with a non-ionic α-1-6 linked glucopyranose units. However, it 
separates from the dextran because these units are pure linear oligomers arranged in a 
matrix-like structure with interchanging iron molecules, and with an average size of 5.2 
glucose units and an average molecular weight of 1000 Da. The resulting matrix contains 
about 10 iron molecules per one isomaltoside pentamer in a strongly bound structure that 
enables a controlled and slow release of bioavailable iron to iron-binding proteins with 
little risk of free iron toxicity (Figure 10) [27].  
 
Figure 10 – Matrix structure of Monofer with ferric iron (red balls) layered between the shell oligomers (blue squares) which 
enables a controlled and slow release of iron [68]. 
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Moreover, the lack of immunogenic branched polysaccharides used in iron 
Cosmofer® and Dexferrum®, prevent anaphylaxis. This allows iron isomaltoside 1000 to 
be administered safely as a rapid high dose IV infusion or bolus injection (doses over 1000 
mg with a maximum single dose of 20 mg/kg of body weight), without a test dose, (doses 
over 1000 mg with a maximum single dose of 20 mg/kg of body weight) and it can achieve 
a 15 minutes administration of 0-5 mg/kg of iron. This can offer considerable dose 
flexibility, including the possibility of providing full iron repletion in a single infusion, 
offering convenient one hospital visit for a wide range of patients [27, 67]. 
Following IV administration, Iron isomaltoside is either metabolized or excreted. 
Due to the size of the complex, only small quantities of iron are eliminated in urine and 
faeces. The distribution volume is 3.0-3.5 L [69], the plasma half-life is 5 hours for 
circulating iron and 20 hours for total iron (bound and circulating) [67]. 
 
The main characteristics of each IV iron materials are represented in Table 5 
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 Table 5 - Characteristics of the different Iv iron materials (Dexferrum®, Cosmofer®, Ferrlecit®, Venofer®, Feraheme®, Ferinject®, Monofer®). 
Unless stated otherwise in the table, the values were obtained from two papers on IV iron, [27]  and [70]. 
 
Product 
HMW-ID 
(Dexferrum®) 
 
LMW-ID 
( Cosmofer®, 
USA)  (Infed®, 
Europe) 
Ferric 
Gluconate 
(Ferrlecit®) 
Iron sucrose 
( Venofer®) 
Ferumoxytol 
( Feraheme®) 
Ferric 
carboxymaltose 
( Ferinject®) 
Iron 
Isomaltoside 
( Monofer®) 
Mineral 
phase 
 
 
 
 
Akaganeite[71] 
 
 
 
Akaganeite 
 
Akaganeite 
Mixture of 
Akaganeite + 
2-line ferrihydrite 
 
Magnetite + 
Maghemite 
 
 
Akaganeite 
 
 
Akaganeite 
 
 
Core Size 
(nm) 
20-35 [22] 4.4-5.6   
2.0-4.1 
[8][26] 
3.2-5.0  6.2-6.4  4.3  4.2-6.3  
Shell 
Branched Dextran 
polysaccharide (α-
D-glucopyranosil 
units)[42] 
Branched Dextran 
polysaccharide (α-
D-glucopyranosil 
units)[42] 
Gluconate + 
loosely 
associated 
sucrose 
Sucrose 
Polyglucose 
sorbitol 
carboxymethyl
ether 
Branched 
carboxymaltose 
polysaccharides 
Linear α1-6 
glucopyranose 
NP Size 
(nm) 
30±10 [22] 12.2  10 [51] 7-8.3 [26] 23.6-30 [62] 
 
23.1 [8]  
 
9.9  
Molecular 
Weight 
265kDa [22] 96-165kDa [8] 
38-444kDa 
[51] 
34-60kDa [8] 
731-750kDa [8, 
23] 
150-233.1kDa [8]  150kDa [8] 
Initial 
distribution 
volume (L) 
3.5 3.5 6 3.4 3.16 3.5 3.4 
Plasma 
Half-Life (h) 
60 20 1 6 15 16 20 
Labile Iron 
Release 
- - +++ +- - - - 
Direct iron 
donation to 
transferrin 
(% of 
injected dose 
1-2 1-2 5-6 4-5 <1 1-2 <1 
Test dose  Yes Yes No Just in Europe No No No 
Iron content 
(mg/mL)  
50 50 12.5 20 30 50 100 
Maximal 
single dose 
(mg) [27] 
20mg/kg 20mg/kg 125mg 200mg 510mg 
15mg/Kg 
Single dose limit: 
1000mg 
20mg/kg 
Pre-
medication  
Total dose 
infusion only 
No No No No No No 
Adverse 
Events 
Anaphylaxis, 
Dyspneia, back 
pain, chest pain, 
pruritus, 
hypotension [72] 
Anaphylaxis, 
Dyspneia, chest 
pain, hypotension, 
nausea, vomiting 
[72] 
Dyspneia, 
Nausea, 
Chest Pain, 
Vomiting, 
Hypotension 
[72] 
Nausea, 
Vomiting, 
Hypotension, 
Dyspneia, 
Dizziness, 
Peripheral 
Edema, Infused 
related [72] 
Diarrhea, 
nausea, 
dizziness, 
hypotension 
[64] 
Headaches, nausea, 
rash, 
hypophosphatemia 
[73] 
Arthralgia, 
myalgia, fever 
Life-
threatening 
AEs 
(×10
6
doses)  
11.3 3.3 0.9 0.6 Not known Not known Not known 
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2.6 Negative outcomes of IV iron therapy in clinical practice 
Over the years, with the development of new IV iron materials, which have 
improved safety and efficacy, the benefits of IV iron have been increasingly realised. 
However, every material is not free from negative outcomes (see Table 3) and the 
reluctance in prescribing this effective treatment could be explained by serious adverse 
effects of iron dextran, specially associated with repeated injection [56, 74]. Much of the 
published work regarding adverse reactions focuses on the experience with this material 
(mostly HMW-ID) with rates of anaphylaxis reported to be as high as 0.6% with adverse 
reactions seen in up to 26% [75]. In fact, the case fatality rate for iron dextran–associated 
anaphylaxis was reported to be as high as 15.8% between 1976 and 1996 (31 deaths in 196 
allergic events) [76]. These anaphylactic reactions are not dose related and they are 
mediated by a preformed Immunoglobulin E antibody to the dextran coating, with the 
majority of symptoms being cutaneous manifestations and respiratory difficulties [75].  
Iron gluconate and particularly iron sucrose have a low frequency of side effects in 
low doses and they are mostly related with the anaphylactoid type reactions which, in 
opposite to anaphylaxis, are non-IgE-mediated but cause similar symptoms such as 
breathlessness, wheezing, arthralgia, myalgia, abdominal or back pain, nausea, vomiting 
and hypotension [13, 56]. This is probably due to the iron component and not to the 
chemistry of the carbohydrate shell, since the lability profile of these small complexes and 
the consequent capacity of iron to be released too rapidly may overload the ability of Tf to 
bind it, leading to the increase of non-transferrin bound iron (NTBI). The high levels of 
this form of iron is the primary cause of all the free iron reactions and the resulting 
anaphylactoid symptoms in the second generation of IV irons [77]. NTBI iron becomes 
highly catalytic and can promote oxidative stress. The one-electron reduction of O2 by Fe
2+
 
results in superoxide formation, which in turn leads to the well-known Haber-Weiss and 
Fenton reaction generating hydroxyl radical (OH
•
) in the following sequence [78]: 
 
(1) Fe2+ + O2          Fe
3+
 + O2
 -• 
 
(2) 2O2
-• 
+ 2H
+         
   H2O2 + O2                                    (Haber-Weiss Reaction) 
 
(3) Fe2+ + H2O2              OH
• 
+ OH
− 
+ Fe
3+
       (Fenton Reaction) 
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The hydroxyl radical is the most powerful oxidant encountered in biological 
systems and will attack proteins, nucleic acids and carbohydrates, initiate chain-
propagating lipid peroxidation [78] resulting in the formation of alkoxyl and peroxyl 
radicals [79]. NTBI can also cause cytotoxicity from oxidative stress by changes in the iron 
metabolism especially in the liver where NTBI is taken up preferentially after being 
cleared from the plasma [35]. The exact mechanism of NTBI-uptake is not known, but it is 
quite possible that the NTBI transporters such as the endosomal divalent metal transporter 
1 (DMT-1) and the membrane putative zinc transporter ZIP14 [80] may be overexpressed 
under the conditions of iron overload, in a way that it will further increase iron uptake 
through NTBI and a consequent increase of the intracellular LIP. This will deactivate the 
iron response element/iron response protein (IRE/IRP) regulatory system, stimulating the 
cell to increase ferritin synthesis and decrease TfR1 expression. The ultimate outcome is a 
decreased uptake from Tf-Fe via TfR1 and an enhancement of the oxidative cell damage 
by the elevated LIP (Figure 11) [81]. 
Other in vitro and in vivo manifestations of the high NTBI levels associated to 
lability in iron sucrose and ferric gluconate are the direct iron donation to Tf (Table 5), 
neutrophil dysfunction and bacterial growth enhancement. In fact, even in low doses, iron 
sucrose has been associated with Tf oversaturation, oxidative stress and enhanced bacterial 
growth in vitro. Although there is no strong clinical evidence for an association of IV iron 
with infection, NTBI makes iron more accessible to bacterial growth and can enhance 
infection [83]. NTBI associated with parenteral iron administration can also promote 
Figure 11 - Cellular outcomes occurring when the serum NTBI is too elevated after IV iron administration [82]. 
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neutrophil damage and consequent loss of migration and killing function by the saturation 
of lactoferrin in iron overload which can decrease the host resistance to bacterial infection. 
This protease destroys the Gram-bacteria by degradation of the outer membrane [84].  
In contrast to the iron dextran-induced anaphylaxis, the "free iron" reactions seem 
to be dose-related. For example, NTBI occurs to a smaller degree after application of iron 
sucrose doses of 50 mg or less, but in higher doses, exaggerated iron levels happen more 
often, maybe due to impaired phagocyte function [85]. Side effects occurred in 0.9% of the 
patients receiving 100 mg/10 min of iron sucrose, but in 5.9% of the patients receiving 200 
mg/10 min  iron sucrose [44]. In consequence, ferric gluconate and iron sucrose require 
multiple and/or relatively time-consuming administration regimens [86] and they are useful 
for only low-dose administration, because its toxicity limits the dose to a maximum single 
administration of just 125 mg and 200 mg, respectively, in opposition to the fewer and 
larger dosage required of ferumoxytol, ferric carboxymaltose and iron isomaltoside [13].  
Epidemiologic data have also raised concerns about a possible association between 
augmented body iron stores and an increased risk of atherosclerosis and cardiovascular 
disease [87]. 
Since ferumoxytol, ferric carboxymaltose and iron isomaltoside are robust with a 
low immunological shell structure, they release minimal detectable free iron compared 
with other iron agents, they are also well tolerated and have a low incidence of side-effects 
associated. Similar to iron dextran, they have the advantage of a slower dissociation rate of 
iron from the complex than iron sucrose and iron gluconate, but they have a lower 
indication of problems with anaphylaxis [88] due to the non-dextran coating. However, the 
FDA failed to approve ferric carboxymaltose for distribution in the USA due to 
unexplained hypophosphatemia [89] and also because of an increased number of adverse 
cardiac events and an imbalance in death rates in the treatment arm compared to the 
control arm in different randomized controlled trials [65]. Although not clearly known, 
ferric carboxymaltose positive surface might be the reason, because, when in circulation, 
negatively charged phosphate could potentially be trapped by electrostatic interaction with 
the surface of the material, explaining the mechanism behind the induced 
hypophosphatemia [27]. On the other hand, it has been suggested that the 
hypophosphatemia associated with parenteral iron therapy could be mediated by Fibroblast 
Growth Factor 23 (FGF-23) [68]. 
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Iron isomaltoside is the latest IV iron and it was supposed to overcome most of the 
negative aspects of the previous IV preparations, and although there is a limited clinical 
data on its safety, there are already reports of AEs happening after administration of 
Monofer® to CKD and IBD patients with associated anaemia [69, 90].  
Table 6 shows a summary of the FDA’s adverse event reports by serious outcome 
for first and second generation IV iron products since their initial marketing to mid-April 
2007 [72]. 
 
 
Although the clinical side effects of the IV iron materials are well documented in 
literature, there is still unexplained occurrence of side effects especially in third generation 
materials, ergo there is a need to fill these gaps by in depth work about the relationship 
between the physicochemical properties (i.e. agglomeration, particle size, iron dissolution, 
mineral phase, redox state of the iron in the core, and surface properties) and the 
occurrence of these side effects.  
 
2.7 Ideal IV iron 
An ideal preparation for IV iron replacement therapy should balance effectiveness 
and safety.  
Such IV iron material would allow the administration of large doses in a short 
period of time to allow the replenishment of iron stores in one infusion and the reduction of 
the need for blood transfusions; to improve convenience of treatment and patients 
management through increased compliance, and, finally, to increase staff efficiency thus 
reducing costs. As for the latest generation of IV iron preparations, such preparations 
would lack dextran since this would result in low immunogenicity and no requirement for a 
Drug Cases Serious Death Hospitalized LT
a
 Interv
b
 
Dexferrum
c
 698 524 24 160 157 214 
INFeD
d
 612 478 43 188 152 90 
Iron dextran
e
 124 94 7 42 42 32 
Ferrlecit
f
 322 222 11 125 53 72 
Venofer
g
 79 64 2 40 8 14 
Table 6 - Number of U.S. cases of Adverse Events Entered in AERS for Selected Parenteral Iron Products, and Types of 
Outcomes, from Each Product’s Marketing to Mid-April, 2007 [5].  a = Life threatning, b = Required intervention; c, d, f 
and g were marketed from 1996, 1992, 1999 and 2000, respectively; and e refer to Dexferrum, INFeD or previously 
marketed iron dextrans [72]. 
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test dose. In addition, a robust core-shell complex would provide a stable binding of the 
iron to its carrier molecule in serum until it is taken up into the macrophage for transfer to 
Tf or storage, because the non-specifically binding of labile iron to other serum molecules 
or the quick saturation of Tf binding site through direct transfer of iron to Tf, could result 
in free radicals formation leading to oxidative stress and a greater probability of side 
effects [35, 60].  
Although, not fully understood, particle size does seem to impact on the efficiency 
of iron delivery from IV iron. Preliminary studies seem to imply that a particle with a size 
greater than 5.5 nm considerably avoids renal clearance and allows a higher macrophage 
uptake limiting direct iron donation to Tf [31]. In fact, the renal elimination rate should be 
below 1% of the dose, and there should be practically no iron detectable in the proximal 
tubule [91]. Sizes above 30 nm are mainly taken by the liver and spleen (i.e. macrophages) 
which associated with longer circulation times could result in enhanced tissue 
accumulation or could be internalized in endothelial cells with a lower rate of endocytosis 
than the macrophages, and it is yet to be understood if this is beneficial [33].  
Furthermore, nanoparticles surface charge will also directly influence the extent of 
cell–nanoparticle interactions and toxic potential of the nanoparticles. In general, cationic 
particles have been described to be the least stable and exert the greatest cytotoxic effects 
(e.g. hypophosphatemia). Although the reduction in positive charges might accompany a 
diminished protein coating in circulation and cellular internalization, it is important to find 
the optimal balance between a lack of toxicity and internalization efficiency. Moreover, for 
quantum dots (i.e. nanosized semiconductor materials), it has been shown that the 
functional groups introduced at the NP surface have a great effect on the nanoparticles 
toxicity with the carboxyl coatings being the best tolerated by cells [92]. 
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3. Techniques for the characterization of IV 
iron materials 
 Cosmofer®, Venofer®, Ferinject® and Monofer® share the same core chemistry 
but differ in the composition of the carbohydrate shell, as well as, in physical (particle size, 
agglomeration) and chemical (dissolution performance, redox state of the iron in the core) 
properties, which makes them vary substantially in pharmacological behaviour, and 
ultimately, in the efficacy and safety profile.  
However, this relationship is not well understood, and the current project aims to 
fill these knowledge gaps, so a physicochemical characterization of each of the IV iron 
materials was needed to fill the gaps of information about the relationship about the 
physicochemical properties of the nanoparticles and the clinical behaviour and safety of the 
IV iron materials in vivo to potentially point out the main flaws of the constitution of a 
colloidal preparation of IV iron and propose an ultimate safe and efficient material. 
To study the physical and chemical properties of the IV iron preparations, particle 
size analysis in aqueous solutions were conducted to the preparations using water and 
serum mimetic solutions to study the behaviour of the nanoparticles and to relate to what 
they would encounter in the circulation in vivo. A key in vitro assay of lysosomal 
dissolution was performed to test all four materials in a narrower range of lysosomal 
conditions to study the kinetics of the preparations, with the assistance of Inductively 
Coupled Plasma - Optical Emission Spectrometer (ICP-OES). Furthermore, the analysis of 
the IV iron materials by XRD allowed to determine the mineral phase  and crystallinity 
(linked to iron lability, e.g. iron dissolution) of each IV iron material, gathering a more in 
depth information about the structure and composition of the IV iron preparations and to 
consolidate the data already available about this type of characterization [32]. The redox 
state (i.e. valence) of Venofer® was also carried out by linear voltammetry methods to 
possibly determine the unexpected presence of ferrous iron in the nanoparticles core and to 
determine how big its content is in each IV iron. 
 
3.1 In Vitro assays 
Lysosomal dissolution assays was developed to establish the relative chemical 
lability of the preparations in the lysosomal compartment which can be useful to 
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understand how the presence of free iron relates to the likelihood of side-effects and then, 
their bioavailability. The pH chosen was 4.5, 5.0 and 5.5 because the pH 4.5 and 5.0 are 
the border values of the physiological lysosomal pH, which is 4.7. A pH above 5.0 might 
affect lysosomal digestion [93]. However, the pH 5.5 was also selected because the 
common mechanism for cellular iron uptake dictates that after the internalization of iron 
bound to Tf, a proton pump promotes acidification of the endosome to pH 5.5, triggering 
the release of Fe
3+
 from Tf to the endosomal space. The chelating agents used were citrate, 
isocitrate and phosphate because both the low pH environment of endosomes/lysosomes 
and the intracellular Fe-chelating substances (i.e., phosphate, nucleotides, dicarboxylic 
acids (citrate and isocitrate)) are responsible for the solubilisation of iron oxide particles 
[94]. The iron concentrations of 0.1, 0.5 and 1 mM were preferred because although not 
physiological values, they are low, ergo permitting a more obvious variation of the 
percentage of soluble iron with time, and 0.1 is the minimum concentrations that allows the 
detection and quantification of iron concentrations by the ICP-OES in conditions where 
small percentages (~5%) of iron are dissolved between two time-points. All the solutions 
tested were left at 37ºC conditions because it is the temperature that subsists in intracellular 
conditions [95].  
An agglomeration assay was also carried out to determine if any agglomeration can 
occur locally when IV iron preparations are administrated intravenously. As the 
agglomeration of iron nanoparticles should not happen in the presence of serum 
electrolytes after the IV administration, the agglomeration was tested by mixing each IV 
iron material with a serum mimicking solution of phosphate and calcium. The preparations 
were also mixed with fetal bovine serum to determine if any nanoparticle agglomeration 
occurs in a more realistic scenario. 
Finally, linear voltammetry was carried out since it is known that the redox state of 
the iron has substantial impact on the safety of iron treatments. In particular, it is 
recognised that ferric iron is better tolerated than ferrous iron in the same conditions in 
vivo, and also that the administration of ferrous iron leads to the production of free radical 
and systemic toxicity [96]. After developing the suitable method, it was applied to 
Venofer® to accurately characterize the redox state of iron in the stock solution. 
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3.2 Analytical techniques 
3.2.1 Dynamic light scattering (DLS) 
Dynamic Light Scattering (DLS) (Zetasizer, Malvern Instruments), sometimes 
referred to as Photon Correlation Spectroscopy (PCS) or Quasi-Elastic Light Scattering 
(QELS), is a non-invasive, well-established technique, useful to obtain particle sizes 
distributions of the four IV iron preparations available in the UK and to measure accurately 
the hydrodynamic sizes of the IV iron nanoparticles in simple aqueous solutions and in 
serum mimetic solutions. It can be also applied to in vitro assays like the lysosomal 
dissolution assay. 
DLS measure the intensity of light scattered by 0.5 to 6000 nm particles in a 
sample. The intensity changes with time due to the Brownian motion (random diffusive 
motion of microscopic particles suspended in a liquid or a gas) of particles in the 
suspension and this motion increases with decreasing particle size. The intensity 
fluctuations of the scattered light are detected at a known scattering angle by a fast photon 
detector. Here, they are converted into electrical pulses, which fed into a digital correlator. 
A correlation factor from the intensity versus time profile is obtained and this 
exponentially decaying correlation function g2(t) provides the diffusion coefficient of the 
particles. In practice, this means that due to their greater Brownian motion, nanoparticles 
lose correlation more rapidly which can then be related to their size (Figure 12) [97-99].  
 
 
 
Figure 12 - Correlation of the scattered light fluctuations after detection of the scattered light and the 
conversion into electrical pulses [99]. 
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The diffusion coefficient, D, is then related to the radius R of the particles by means 
of the Stokes-Einstein equation and the instrument calculates the hydrodynamic size of the 
particle (Equation 1) [100].  
 
 
 
 
 D is the diffusion coefficient, R is the radius, T is the temperature and η is the 
viscosity. The translational diffusion coefficient will depend not only on the size of the 
particle but also on any surface structure and the concentration and type of ions in the 
medium [98]. 
The events that take place on the DLS are represented in Figure 13 [101]. The size 
obtained by this technique is that of a sphere that has the same translational diffusion 
coefficient as the particle being measured. DLS produces an intensity distribution (Figure 
14) from which, assuming a fixed relationship between scattering intensity and volume, a 
volume distribution can then be estimated.  
 
 
 
  
 
 
 
 
 
 
 
 
 
Equation 1 - Stokes-Einstein equation.  
Figure 13 – Schematic diagram of the events that occur in a conventional Dynamic 
Light Scattering [101]. 
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3.2.2 Zeta Potential 
 Zeta potential (Zetasizer, Malvern Instruments) is a measure of the magnitude of 
the electrostatic or charge repulsion or attraction between particles, and is one of the 
fundamental parameters known to affect stability. The “Zetasizer” calculates the zeta 
potential by determining the electrophoretic mobility and then applying the Henry equation 
(Equation 2) [102].  
 
  
 
 
 
 Z is the zeta potential, UE is the electrophoretic mobility, ɛ is the dielectric constant, 
f(ka) is the Henry’s function (1.0 and 1.5 are usually used to as approximations) and η is 
the viscosity. An important consequence of the existence of electrical charges on the 
surface of particles is that they will exhibit certain effects under the influence of an applied 
electric field. In this case, the determination of zeta potential and ergo the surface charge 
will be induced by the electrophoretic motion – the movement of a charged particle relative 
to the liquid it is suspended in, under the influence of an applied electric field. The essence 
of a classical micro-electrophoresis system is a cell with electrodes at either end to which a 
Figure 14 – Example of particle sizing distribution data of Ferinject (Ferric carboxymaltose) by intensity.  The current 
example shows the measurement of three replicates. 
Equation 2 - Henry equation. 
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potential is applied. Particles move towards the electrode of opposite charge and their zeta 
potential is calculated directly from their mobility (Figure 15) [102]. 
 
 
 
 
 
 
  
  
 
  
 
 Its measurement brings detailed insight into the causes of dispersion or 
agglomeration (clumping of nanoparticles together). Ultimately, it will give information 
about the nanoparticle surface charge at a given pH which may help explaining the data of 
the agglomeration given by the DLS. 
 
3.2.3 Inductively Coupled Plasma - Optical Emission Spectrometer (ICP- 
OES) 
ICP-OES is a rapid and accurate technique to determine concentrations of a wide 
range of elements in solution. Metals and metalloids can be determined at the ultra-trace 
level on μg or μL samples (detection limits of 0.03–10 ng/mL) [103]. In the current 
project, ICP-OES will allow accurate quantification of iron content in the IV iron materials 
to detect different phases (i.e. soluble, nanoparticulated or agglomerated) from samples 
obtained from in vitro assays. 
The technique requires an initial nebulization of the liquid sample into an aerosol. 
This aerosol sample is then transported to the plasma where the temperature is sufficiently 
high (6000–8000 K) so that the sample can be desolvated, vaporized and atomized thus 
breaking chemical bonds and liberating elements. The plasma promotes then the excitation 
Figure 15 - Disposable folded capillary cell representing the micro-electrophoresis system that permits the 
differential mobility of particles according to their surface charge [102]. 
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of the atoms which when returning to their fundamental state, emit radiation. The 
frequency of this radiation is characteristic of the element that emitted it and as such can be 
used for identification purposes. Also, the intensity of the radiation is proportional to the 
concentration of that element within the solution so it can be used for quantitative purposes 
[104]. The major events that happen in an ICP run are illustrated in Figure 16 [105]. 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.4 Voltammetry 
 The potentiostat (Autolab/PGSTAT302N) allows electrochemical studies such as 
voltammetry, for investigations of reaction mechanisms related to redox chemistry. In 
voltammetry we apply a time-dependent potential to an electrochemical cell and measure 
the resulting current as a function of that potential.  
 A modern potentiostat makes use of a three-electrode arrangement – the most 
common ones are the Ag/AgCl reference electrode, the platinum wire auxiliary electrode 
and the mercury working electrode. The working electrode can also be replaced by a 
rotating disc electrode (RDE). The cell also includes a gaseous nitrogen line purge all the 
oxygen out to avoid oxygen-driven redox reactions and an optional stir bar (Figure 17) 
[106, 107]. 
 
  
 
Figure 16 – Chemical events that occur during an ICP-OES 
run of a sample [105]. 
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 In voltammetry we apply a time-dependent potential excitation signal to the 
working electrode changing its potential relative to the fixed potential of the reference 
electrode, and measure the current that flows between the working and auxiliary 
electrodes. When we oxidize an analyte at the working electrode, the resulting electrons pass 
through the potentiostat to the auxiliary electrode, reducing the solvent or some other 
component of the solution matrix. If we reduce the analyte at the working electrode, the current 
flows from the auxiliary electrode to the cathode. In either case, the current from redox 
reactions at the working electrode and the auxiliary electrodes is called a faradaic current, and 
it is presented as a specific peak which size is directly proportional to the concentration of 
the analyte specie oxidized/reduced [106, 108]. 
 There are several different voltammetric methods that differ in terms of the type of 
working electrode, how we apply the potential, and whether we include convection 
(stirring) as a means for transporting of material to the working electrode. Among the 
several voltammetric modes, we have the differential pulse polarography which is a 
frequently used voltammetric determination mode. It uses a Dropping Mercury Electrode 
(DME) and we obtain a limiting current instead of a peak current. When a Hg drop 
separates from the working electrode surface and falls to the bottom of the electrochemical 
cell, it mixes the solution. Each new Hg drop, therefore, grows into a solution whose 
composition is identical to the bulk solution. The oscillations in the current are a result of 
the Hg drop’s growth, which leads to a time-dependent change in the area of the working 
electrode where the current is measured twice per cycle: before applying the pulse at the 
Figure 17 - Typical electrochemical cell for voltammetry: three-elecrode arrangement 
plus the N2 purge line, all immersed in the solution where the analytes are present [106] 
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end of the cycle. The difference in the two currents gives rise to the peak-shaped 
voltammogram (Figure 18) [106]. 
 
We call the resulting plot of current versus applied potential a voltammogram 
(Figure 19), and it is the electrochemical equivalent of a spectrum in spectroscopy, 
providing quantitative and qualitative information about the soluble species involved in the 
oxidation or reduction reaction [106, 108].  
 
  
Figure 18 - Potential-excitation signal and voltammogram for a differential pulse polarography scan. When measuring a 
change in current, ip, the current at point 1 is subtracted from the current at point 2. Ƭ is the cycle time Ep is a fixed or 
variable pulse potential; Es is the fixed change in potential per cycle, and tp is the pulse time [106]. 
Figure 19 - Typical linear voltammogram regarding an iron valence analysis with the two peaks referred to the soluble 
ferrous and ferric iron present when reducing potentials are applied. The plot is current I(A) versus potential U(V). 
Experimental output retrieved from a method of polarographic determination of iron from a sucrose injection 
solution. 
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This current vs concentration relationship will allow a quantitative analysis of the 
ferrous and ferric iron present in the stock solutions of the IV iron preparations by Linear 
voltammetry simply by applying a potential increasingly negative until it reaches the 
potential of reduction of Fe
3+
 to Fe
2+
 and then the potential of reduction of Fe
2+
 to Fe
0
, 
giving two distinct peaks. 
 
3.2.5 X-ray diffraction 
 X-ray diffraction is a rapid analytical technique used for phase identification of 
solid matter, especially crystalline substances. Solid matter can be described as amorphous 
– where the atoms are arranged in a random way similar to the disorder we find in a liquid 
–, or as crystalline – that act as three-dimensional diffraction gratings for X-ray 
wavelengths where the atoms are arranged in a regular pattern, and exist as smallest 
volume units that by repetition in three dimensions describes the crystal. The smallest 
volume unit is called a unit cell. The dimensions of the unit cell is described by three axes 
a, b and c and  the angles between them alpha, beta, gamma [109], which defines the 
crystallization system. 
 X-ray diffraction is based on constructive interference of monochromatic X-rays 
and a crystalline sample. These X-rays are generated by a cathode ray tube, filtered to 
produce monochromatic radiation and directed toward the sample. The interaction of the 
incident rays with the sample produces constructive interference (and a diffraction ray) 
when conditions satisfy Bragg’s Law [109, 110]:   
     nλ= 2d sin θ 
λ – Wavelength of the x-ray beam 
θ – incident angle  
d – distance between atomic layers in a crystal 
n – order of the diffraction peak (integer number) 
 This law relates the wavelength of the electromagnetic radiation (λ) with the 
diffraction angle (θ) and the lattice spacing between atomic plans (d). These diffracted X-
rays are then detected, processed and counted. By scanning the sample through a range of 
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2θ angles, all possible diffraction directions of the lattice should be attained due to the 
random orientation of the powdered material. Conversion of the diffraction peaks to d-
spacings allows identification of the mineral because each mineral has a set of unique d-
spacings. This is compared with standard reference patterns [109, 110]. 
The sample preparation is easy, and X-ray powder diffraction should be able to 
quickly identify the mineral phases of all the materials, even if there is a multiplicity of 
components in a mixture. 
4. Materials and Methods 
4.1 Materials 
 
Table 7 – List of the compounds used in the lysosomal assay, in the serum mimetic solution and in voltammetry. 
Compound Chemical Formula Supplier 
Sodium Phosphate Dibasic Na2HPO4 Sigma-Aldrich 
Calcium Chloride dihydrate CaCl2·2H2O Sigma-Aldrich 
Sodium Chloride NaCl Sigma 
Sodium Citrate Na3C6H5O7 Sigma-Aldrich 
Sodium acetate anhydrous NaC2H3O2 Sigma 
(+)-Potassium Ds-threo-isocitrate monobasic KC6H7O7 Sigma-Aldrich 
Citric acid C6H8O7 Sigma-Aldrich 
Mercury Hg Sigma-Aldrich 
Iron(III) chloride hexahydrate FeCl3·6H2O Sigma-Aldrich 
Iron(II) sulphate hepahydrate FeSO4·7H2O Sigma 
Sucrose C12H22O11 Sigma 
Dextran (1000kDa) from Leuconostoc mesenteroides (C6H10O5)n Sigma-Aldrich 
Dextran (5000kDa) from Leuconostoc mesenteroides (C6H10O5)n Sigma-Aldrich 
Fetal Bovine Serum Not available GIBCO 
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Table 8 – List of the IV iron preparations used as samples in the experimental work [43, 65]. 
Compound Chemical Formula Supplier 
Cosmofer® (LMW-
ID) 
Not found Pharmacosmos 
Venofer® (Iron 
Sucrose) 
[Na2Fe5O8(OH)·3H2O]n·m(C12H22O11)[48] Vifor Pharma 
Ferinject® (Ferric 
carboxymaltose) 
[FeOX(OH)Y(H2O)Z]n[{(C6H10O5)m(C6H12O7)}I]k[70] Vifor Pharma 
Monofer® (Iron 
isomaltoside 1000) 
Not found Pharmacosmos 
 
4.2 Methods 
4.2.1 XRD analysis  
The four IV iron materials were completely dried at 45ºC and the powders were 
milled and analysed by X-Ray Diffraction, at the Earth and Environmental Department at 
the University of Leeds. Each sample was mixed with ethanol and pipetted onto a low 
background silicon holder.  The diffraction data was collected with a Philips PW1050 
Powder Diffractometer using Cu K-alpha radiation and a Ge secondary 
monochromator.  The scanning range was 5-70 deg 2 theta at a speed of 0.8 deg/min and a 
step size of 0.01 deg.  TRACES software with the ICDD (International Centre for 
Diffraction Data) database was used to process the data. The percentage of solid matter 
was also calculated from the powders obtained. 
4.2.2 Iron content determination by ICP-OES 
Cosmofer®, Ferinject® and Monofer® were diluted with 5% nitric acid (to 
completely dissolve the iron) while Venofer® was diluted using a more concentrated 
solution of nitric acid (70%) because of the difficulty encountered with 5% nitric acid. 
Nitric acid is necessary because sample preparation for ICP-OES analysis requires acid 
digestions to avoid the existence of solid analyte in the sample. Subsequently, dilutions 
were made with 5% nitric acid, in triplicate, for each IV iron to adjust the concentration of 
iron to the range of the different standards used (0-100 ppm). The IV iron preparations 
were then analysed by ICP-OES (JY2000, Horiba Jobin Yvon) to determine the iron 
concentration of the solutions. 
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4.2.3 Determination of nanoparticle agglomeration  
Initially, the preparations were diluted to 50ppm of iron with ultrapure water, in 
triplicate, using the iron concentrations obtained by ICP-OES (experiment 4.1.2) and were 
analysed by DLS do determine their partice size in the simplest aqueous solution.  
The same procedure as above was repeated, but instead of water, an aqueous 
solution of 2.4 mmol/L of total calcium (CaCl2·2H2O), 1.3 mmol/L of phosphate 
(Na2HPO4) and 0.9% of NaCl at pH 7.42 was used, to mimic the conditions that the IV 
iron would face in the circulation [111, 112].  
All the samples were analysed by DLS immediately after being prepared, except 
the serum mimetic solutions. Due to this delay, the pH had to be adjusted again right 
before the analysis by DLS. The resulting particle size distribution was obtained and 
processed by the “DTS (Version 4.1)” software (Malvern Instruments Ltd., Malvern, UK).  
The concentration of precipitated, nanoparticulated and soluble fractions of calcium 
and phosphate were determined by ICP-OES to determine if there is aggregation 
(association of both ions by electrostatic interaction) in electrolyte solutions of calcium and 
phosphate. For this we used the phosphate and total calcium solution prepared before and a 
fresh solution with physiological concentrations of phosphate and calcium in its free ionic 
form, 1.2 mmol/L of calcium (CaCl2·2H2O). To study the fractions of calcium and 
phosphate in each solution, i. e. soluble, nanoparticulated and precipitated, sets of three 
aliquots were collected for each fraction. One set of aliquots was used to calculate the total 
concentration of calcium and phosphate in the solution; a second set was centrifuged 
5minutes with 13000 rpm and the supernatant was analysed to get the concentration of the 
nanoparticulated calcium and phosphate. The third set was ultrafiltred by centrifugation (5 
minutes, 13000 rpm) through a membrane of 3 kDa to retain any salt in nanoparticulated 
form, and then analysed on the ICP-OES to determine the concentration of the soluble 
calcium and phosphate. All samples were diluted in 5% nitric acid and to get final samples 
with iron concentrations within the calibration curve (0-5 ppm for calcium and phosphate). 
The calculations used were: 
Fe precipitated (mM):             Fetotal – Fesupernatant 
Fe nanoparticulated (mM):      Fesupernatant – Fesoluble 
Fe soluble (mM):                    Fetotal – (Feprecipitated + Fenanoparticulated) 
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Furthermore, each material was diluted to 300 ppm of Fe in Fetal Bovine Serum 
(FBS) or in 0.9% NaCl. Each suspension was incubated at 37ºC with stirring for 30 
minutes, after which aliquots (in duplicate) were transferred to 1000 kDa filter eppendorfs 
to be centrifuged 15 minutes with 13000 rpm. Both filtrates plus a non-filtrated aliquot 
were diluted five times in 5% nitric acid and were analysed by ICP-OES using the 
preferred standard range. The calculations used were: 
% Fe agglomerated (1000 kDa):               [(Fetotal – Fefiltered, 1000)/ Fetotal] × 100 
% Fe agglomerated (0.1 µm):                   [(Fetotal – Fefiltered, 0.1)/ Fetotal] × 100 
% Fe filtered (100 0kDa):                      (Fefiltered, 1000/ Fetotal) × 100 
% Fe filtered (0.1 µm):                      (Fefiltered, 0.1/ Fetotal) × 100 
Additionally, the four IV iron materials were diluted to 1000 ppm in ultrapure water 
and the zeta potential was measured firstly with no pH adjustment and then with pH = 
7.35. The zeta potential was obtained and processed by the “DTS (Version 4.1)” software 
(Malvern Instruments Ltd., Malvern, UK).  
 
4.2.4 Lysosomal dissolution  
The first part of this assay was the determination of the optimal conditions of pH, 
iron concentration and chelating agent to obtain the most representative results, using 
Venofer® as the sample. Then, with the method optimized, it was applied to all materials. 
Assuming the iron concentration of Venofer® obtained by the ICP-OES in 
experiment 3.1.2, the necessary dilutions with a 10 mM of fresh citrate buffer were made 
to get a final iron concentration of 0.1 mM (5584 ppb) in a pH 5.0 environment. 
Subsequently, the solution was incubated at 37ºC in a water bath for seven days with no 
further adjustment of the pH. The solution was analysed in the ICP-OES at 0, 15 and 30 
min, 1, 2, 4, 6, 24 and 48h and seven days (the 0 min measurement was done using the 
citrate buffer as sample). At each time-point, aliquots of the solution were taken and 
prepared for ICP-OES measurement of the precipitated, nanoparticulated and soluble iron 
the same way as it was done for 4.2.3 for the calcium and phosphate solution.  
We used the same protocol to perform further dissolution assays with the following 
modifications (Table 9):  
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Table 9 - Four solutions of Venofer® and citrate buffer prepared with different pH and iron concentrations. 
Solution pH [Fe] (mM) Chelating agent 
2 5.0 0.5 
Citrate (10mM) 
3 5.0 1.0 
4 4.5  0.1 
5 5.5 0.1 
6 4.5 0.1 Phosphate (10mM) 
7 4.5 0.1 Isocitrate (10mM) 
 
Once the pH, chelating agent and iron concentrations were chosen, we deviated 
from the physiological conditions by performing a more acidic dissolution of Venofer® 
(pH 2.5 with citric acid as the pH adjuster and chelating agent) to make the dissolution 
quicker. To understand if the results obtained were due to a pH or chelating agent-driven 
dissolution, the four IV iron products were dissolved in the same conditions but without 
citric acid. 
Once established the best conditions to a faster and reproducible dissolution a 
dissolution assay was performed to the four IV irons in the conditions of pH 2.5, 0.1mM of 
Fe and 10mM of citric acid.  
To possibly obtain the same soluble iron yield as the previous dissolution but 
maintaining a more physiological scenario, we tried to optimize the assay by increasing the 
concentration of chelating agent. Two dissolutions of Venofer® were made, both at pH 
4.5, 0.1 mM of Fe but with different concentrations of citrate: 20 mM and 50 mM. 20 mM 
regards the sum of the concentrations of all the organic acids in the lysosome assuming the 
concentration of citrate as being 10 mM, whereas 50 mM is the concentration of citrate in 
the lysosomes of the rubber tree [113]. 
The calculations used were: 
% Fe precipitated:               [(Fetotal – Fesupernatant)/ Fetotal] × 100 
% Fe soluble:               (Fesoluble / Fetotal) × 100 
% Fe nanoparticulated:        100 – Fesoluble (%) – Feprecipitated (%)               
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4.2.5 Linear voltammetry analysis of ferric and ferrous content in Venofer®. 
 The potentiostat (Autolab/PGSTAT302N) was used to analyse the iron redox state 
(ferric and ferrous content) of Venofer® by differential pulse polarography (linear 
voltammetry) using the software 757 VA Computrace and the method VA Application Note 
No. V-127, Polarographic determination of Fe
2+
 in iron sucrose injection solution 
according to USP 26 / NF21 from Metrohm. The working electrode was a Multi-Mode 
Electrode with the Dropping Mercury mode; the auxiliary electrode was a platinum one 
and the reference electrode was a Ag/AgCl one. A ferrous sulphate and ferric chloride 
solution were also analysed to evaluate if the method works. Venofer® was also scanned 
using a Rotating disk electrode (RDE) instead of a mercury working electrode. The sample 
conditions in every scans performed was 20 ppm of iron, diluted in the sodium acetate (150 
g/L) electrolyte solution. Each analysis was performed in triplicate. 
 
5. Results and Discussion 
5.1 XRD analysis  
 The identification and characterization of synthesized materials was carried out by 
powder XRD to determine the mineral phase of Cosmofer® (Figures 20), Venofer® 
(Figure 21), Ferinject® (Figure 22) and Monofer® (Figure 23), which, surprisingly, 
showed akaganeite crystallinity resemblance only in Ferinject®, whereas Cosmofer® and 
Monofer® exhibited amourphousness, and Venofer’s mineral phase profile was masked by 
the sucrose peaks. 
 The XRD characterization of each IV iron products can help to explain the results 
from the lysosomal dissolution because amorphous forms may exhibit distinct physical 
properties compared to crystalline species of the same molecule, such as different 
dissolution profiles. The dissolution advantage of amorphous solids can be negated by 
crystallization due to higher robustness [114]. Particularly, the presence of a crystalline 
arrangement such as akaganeite confers a higher stability to the core because of the ordered 
octahedrally high spin Fe(III) ions coordinated with six oxygen atoms, whereas an 
amorphous solid has the atoms arranged in a random way decreasing the structure order, 
increasing the surface area and making them more easily dissolved with higher rates of 
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iron release. For example, it has been proved that amorphous Fe(OH)3 dissolves at least ten 
times faster than lepidocrocite (γ-FeOOH), which is another oxyhydroxide polymorph like 
akaganeite (β-FeOOH) [115]. 
 Moreover, a higher level of amorphousness has been linked to an increased 
capacity to bind anions, and different types of FeOOH polymorphs have different 
electrolyte affinities, such as the described affinity of akaganeite to phosphate. Thus, not 
only phosphate binds the nanoparticles according to the surface charge by electrostatic 
interaction, but also by electrostatic interaction with the surface of the core and by ligand 
exchange for surface OH groups [116].  
 
Figure 20 - XRD characterization of Cosmofer powder obtained after drying 2mL of stock solution at 45⁰C. An akaganeite 
pattern is represented in red lines. 
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Figure 21 - XRD characterization of Venofer powder obtained after drying 5mL of stock solution at 45⁰C. An akaganeite 
pattern is represented in red lines. 
Figure 22 - XRD characterization of Ferinject powder obtained after drying  2mL of stock solution at 45⁰C. An akaganeite 
and halite patterns are represented in blue and red lines, respectively. The green circles correspond to the halite (NaCl) 
peaks detected. 
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Surprisingly, all four materials should have resembled akaganeite but just 
Ferinject® spectrum matched the akaganeite peaks more faithfully. Ferinject® spectrum 
also showed the clear presence of two of halite’s peaks (marked as two green circles). This 
match helped to confirm the presence of akaganeite in Ferinject® because halite is 
composed by crystals of NaCl, and as mentioned before, chloride is an element present in 
the structure of akaganeite.  
 Cosmofer® and Monofer® seem to be more amorphous as their peaks do not 
match akaganeite ones nor they show the 5000 kDa and 1000 kDa respective dextran peaks 
(see in Appendix). However, it seems like some of the peaks could have corresponded to 
the akaganeite ones if they were not blunted which points towards some unidentified cause 
that could have distorted the original akaganeite structure into another crystalline phase. 
Such causes could have consisted in the unlikely thermal decomposition of the mineral due 
to dry heating at 45ºC because akaganeite is easily converted to hematite at 300ºC but it is 
reported to suffer some transformation below that temperature [117]. The presence of 
water can also be a variable and the loss of the choride ions leads to a loss of stability and 
Figure 23 - XRD characterization of Monofer powder obtained after drying  1mL of stock solution at 45⁰C. An 
akaganeite pattern is represented in red lines. 
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facilitates the transformation of akaganeite to goethite and hematite [118]. So, the lack of 
halite’s peaks in Cosmofer® and Monofer® spectrums can point towards an unexplained 
loss of chloride atoms as a possible source of amorphousness. In case of Venofer®, we can 
confirm the presence of sucrose but its peaks clearly shift the scale up and make de mineral 
phase identification impossible to determine, although we would expect a mixture of 
akaganeite and 2-line ferrihydrite [27].  
Due to the uncertain explanation for this non resemblance to akaganeite and as the 
gathering of the powders is quite simple, it is hard to believe that this might be due to bad 
preparation of the samples. Therefore, we will consider these results in further discussion. 
 The percentage of solid matter was also calculated from the powders obtained 
(Table 10) to relate it with the iron concentration of each stock suspension. 
 
 
 
 
 
 
 
 At 45ºC, the drying occurred very slowly in a way that after two weeks we had to 
collected the powder. Consequently, the percentage of solid matter might have been 
overestimated because of the presence of water in the dried powders. The water 
contamination might explain why Monofer®, the most iron concentrated material 
(1000mg/mL), did not have the highest percentage of solid matter when we was supposed 
to, and why Venofer®, the least iron concentrated IV iron (20 mg/mL), presented the 
highest percentage (44.8%). Ferinject® and Cosmofer® showed different percentages 
28.0% and 17.9%. even though they share the same concentration of iron (50 mg/mL). 
 
5.2 Iron content determination 
The concentration of each IV iron suspension was determined, to see if it matched 
the respective ones described in the vial label (Figure 24 and Table 10). 
 
% of solid matter 
Venofer®  44.8 
Cosmofer® 28.0 
Ferinject® 17.9 
Monofer® 37.3 
Table 10 - Percentages of solid matter obtained 
from the powders of each IV iron material. 
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IV iron Average [Fe] measured (mg/mL) [Fe] expected (mg/mL) 
Venofer® 16.08±0.62 20 
Cosmofer® 57.97±0.81 50 
Ferinject® 70.84±8.34 50 
Monofer® 94.91±9.98 100 
 
As we can see in Figure 24 and Table 10, the obtained concentrations of iron 
showed some deviation from the expected ones in the stock. Although some experimental 
errors in the dilutions could have happened, these differences are most likely related to 
manufacturing variability. Venofer® and Cosmofer® presented the most similar 
concentrations to the respective stock, so the 16.08 mg/mL concentration of iron obtained 
for Venofer® was considered in the preliminary lysosomal dissolutions to determine the 
best iron concentration, pH and chelating agent.  
 
Figure 24 - Comparison of the concentrations (mg/mL) of iron between Cosmofer®, Venofer®, 
Ferinject® and Monofer® measured by ICP-OES and the concentrations expected (i.e. described in 
the vials). 
Table 10- Concentrations (mg/mL) of iron measured and the ones found in the stock solutions for 
Cosmofer®, Venofer®, Ferinject® and Monofer®. 
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5.3 Determination of nanoparticle agglomeration 
The particle sizing performed to Venofer®, Cosmofer®, Ferinject® and 
Monofer®, diluted to 50 ppm of Fe with ultrapure water, gave the actual size of the 
nanoparticles (Figure 25 and Table 11). At the same time, it represented the most 
innocuous scenario that the products would face and the control needed to analyse the 
results of the particle sizing of the IV iron diluted in a Ca
2+
/PO4
3-
 solution. 
The 50 ppm concentration was chosen specifically because it is slightly lower than 
62.5 ppm, which is the concentration estimated in the blood if the maximum dose of 
Venofer® was administrated (200 mg) assuming its distribution volume of 3.2 L [57]. This 
way, we can obtain and compare the possible nanoparticle agglomeration between all the 
materials in iron concentrations (50 ppm) not considered dangerous for the human with 
few reports of AEs. 
 
 
 
 
 
 
 
 
 
 
 
 
IV iron Average particle sizes measured (nm) Particle Sizes expected (nm) 
Venofer® 8.2±0.12 7-8.3 [26] 
Monofer® 10.7±0.08 9.9 [27] 
Cosmofer® 11.3±0.09 12.2 [27] 
Ferinject® 22.9±0.96 23.1 [27] 
Graphic 25 - Comparison of the particles sizes (nm) measured for the four IV materials at 50ppm of Fe 
and the ones in literature. 
Table 11 - Particle Sizes (nm) obtained for  Venofer®, Monofer®, Cosmofer® and Ferinject® diluted in water (50mg/L 
of iron) and the particle sizes in literature. 
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 In these water conditions, no agglomeration was seen, the particle sizes obtained 
presented low standard deviations and the peak averages were similar to the ones described 
in literature (figures of the size distribution in Appendix). As shown in Table 11, the 
average nanoparticles sizes were: Venofer® = 8.2 nm < Monofer® = 10.7 nm < 
Cosmofer® = 11.3 nm < Ferinject® = 22.9 nm. However, when we measured the particle 
sizes in the same iron concentration conditions but in a solution with serum concentrations 
of phosphate (1.3 mM) and total calcium (2.4 mM), the nanoparticle sizes of Cosmofer®, 
Ferinject® and Monofer® became slightly bigger, ergo diverging from the ones got from 
the water dilution (Table 12). Venofer® showed many different peaks and the deviation 
was too high to determine an accurate particle size. 
 
Table 12 - Particle Sizes (nm) of Venofer®, Monofer®, Cosmofer® and Ferinject® diluted in the calcium and phosphate 
solution (50mg/L  of iron). 
 
 
Cosmofer® (Figures 26) and Ferinject® (Figure 29), showed large agglomerates, 
whereas Venofer® (Figure 27) showed much higher peak deviations at the lower particle 
sizes and also a more noticeable presence of large agglomerates. Overall, the presence of 
these peaks in a bigger particle size range gives evidence of agglomeration between 
nanoparticles in all the materials but Monofer® (Figure 28).  
IV iron Average particle sizes measured (nm) Average particle sizes in water (nm) 
Venofer® Not applicable (high deviation) 8.2±0.12 
Monofer® 11.7 ± 0.98 10.7±0.08 
Cosmofer® 14.3 ± 0.17 11.3±0.09 
Ferinject® 23.8 ± 0.47 22.9±0.96 
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Figure 26 - Statistics graph of the size distribution by volume of Cosmofer® diluted in the calcium and phosphate 
solution (50mg/L of iron). Total of nine measurements. 
Figure 27 - Statistics graph of the size distribution by volume of Venofer® diluted in the calcium and phosphate 
solution (50mg/L of iron). Total of nine measurements. 
Figure 28 - Statistics graph of the size distribution by volume of Monofer® diluted in the calcium and phosphate 
solution (50mg/L of iron). Total of nine measurements. 
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Further ICP-OES measurements to the same calcium and phosphate solution 
proved that the agglomeration was not due to the formation of insoluble salts from this 
solution (Table 13). 
 
Table 13- Concentration of the precipitate, nanoparticulated and soluble fraction of phosphate and total calcium in 
the already prepared solution. 
 
Average 
 
 
precipitate nanoparticle soluble Total 
 
mM mM mM mM 
Phosphate 0.03 ± 0.01 0.04 ± 0.04 1.39 ± 0.03 1.47 
Total calcium 0.01 ± 0.01 0.01 ± 0.01 2.14 ± 0.01 2.16 
 
As mentioned before, oxydydroxyes play a significant role in sequestering 
electrolytes because of their large surface area and strong affinity for some anions such as 
the affinity of akaganeite for phosphate. This preferable anion adsorption is highly 
dependent on the pH and on the hydroxyl surface site composition.  
In particular, akaganeite has a pHPZC (pH in the point of zero charge, at the core 
surface) of 7.9 ± 0.1 [119], thus, the core surface of all the IV iron materials should have 
had a positive charge at the pH 7.4 of the phosphate and calcium solution. In these 
conditions, the agglomeration evidences in Venofer®, Cosmofer® and Ferinject® can be 
explained by the electrostatic interaction between the positive charges of the core surface 
and the negative charged phosphate ions (mechanism described in Figure 30 [120]). 
Figure 29 - Statistics graph of the size distribution by volume of Ferinject® diluted in the calcium and phosphate 
solution (50mg/L of iron). Total of nine measurements. 
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However, this interaction here proposed is only valid if phosphate can overpass the 
physical barrier of the carbohydrate shell and the repelling negative charge at physiological 
pH present in Venofer® and Cosmofer®. Considering the high lability associated to the 
second generation materials such as Venofer®, it makes sense that the highest evidences of 
agglomeration in this Venofer® is due to a weak shell-core interaction that allows the 
phosphate to pass through the sucrose coating and interact with the iron. In case of 
Ferinject®, it is reported to become more positively charged in the nanoparticle surface 
with increasingly acid pH [27], so the affinity to phosphate might happen in the surface, 
even because Ferinject® is a very robust IV iron with strong coating protection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30 - Scheme of the possible mechanism of agglomeration between the iron nanoparticles and 
the ions of calcium and phosphate. The standard mechanism of electrostatic adsorption between the 
phosphate and the oxyhydroxide is described in the box at a pH below the pH of point of zero charge 
[120]. 
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Conversely, Monofer® shares the same amorphousness and negative surface 
charge with Venofer® and Cosmofer® and it did not show any sign of agglomeration, so 
another mechanism of iron core-phosphate adsorption must be the cause, and that might be 
the ligand exchange for surface OH groups with the formation of inner sphere complex 
(mechanism described in Figure 31) [120]. Moreover, the phosphate adsorption by this 
mechanism can be enhanced through hydroxyl surface site availability and this last one 
depends on the level of amorphousness and disorder of the mineral phase. So, although not 
available in the XRD data, the synthetic 2-line ferrihydrite considered to be present in 
Venofer® has a much more poor order than akaganeite in a way that its surface is more 
heterogeneous with a bigger surface area than akaganeite, which gives a number of surface 
OH group available for adsorption of 12.7 × 10
2
 meq/g while akaganeite has just 4.5 × 10
2
 
meq/g [118]. Therefore, the higher evidences of phosphate adsorption in Venofer® can be 
due to a larger amount of ligand sites to the phosphate ions ergo increasing the affinity 
between this ion and the core surface.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The phosphate and calcium solution represented just a fraction of the molecules and 
electrolytes exposed to IV iron materials when these are in the blood, so the agglomeration 
was also assessed by diluting each IV iron material in FBS (similarity in composition to 
the Human serum). The main goal was to develop a method that could trap the fraction of 
agglomerated nanoparticles by filtration and would let all the proteins and the non-
Figure 31 - Mechanism of formation of inner sphere complex by phosphate exchange for hydroxyl 
groups, as an explanation to the nanoparticle adsorption with phosphate [120]. 
69 
 
agglomerated nanoparticles pass through the filters. So, 1000 kDa filters were chosen 
because the largest protein in the human serum is albumin with 67 kDa and the biggest 
nanoparticles belong to Ferinject® with a molecular weight around 750 kDa [17]. A first 
assay aimed the determination of the possible agglomeration in the serum conditions the 
IV iron materials would encounter if they were administrated undiluted, by diluting each 
material directly with FBS to 300 ppm of Fe. A parallel dilution with saline worked as the 
control as we do not expect any kind of nanoparticle trapping (Figure 32). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 At this high, but permitted concentration, the trapping of iron was only evident in 
Venofer® (6.79 ± 0.81%) and Monofer® (3.89 ± 0.44%) whereas Cosmofer® and 
Ferinject® presented large and inconclusive error bars which implicates that a repeat of the 
assay should be done. Additionally, the high variability obtained with Ferinject® diluted in 
saline does not confirm agglomeration, but, at the same time, as the IV administration 
strategy always requires the dilution of the preparation in saline solution immediately 
before drip infusion, this deviation raises some concerns about the possibility of the 
Ferinject® nanoparticles agglomerate in saline conditions.   
Figure 32 - % of iron filtrated of the 4 IV irons, after 1000kDa filtration by centrifugation, 
mimicking an undiluted administration. The red bars are the control. 
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 One must consider that the potential agglomeration in Venofer® and Monofer® 
can also be due to a manifestation of the normal mode of action of the nanoparticles after 
administration, i.e., the agglomerated nanoparticles might have suffered the normal serum 
protein coating that is necessary to transport the nanoparticles to the macrophages, where 
they are processed. Nevertheless, even if this is true, the agglomeration seen in the calcium 
and phosphate solution make us believe that these percentages of trapped nanoparticles are 
also due to unwanted binding to serum components such as electrolytes, even not knowing 
if 6.79 ± 0.81% and 3.89 ± 0.44% are high enough to have a negative impact in the safety. 
A second assay aimed the determination of the possible agglomeration in the serum 
conditions the IV iron materials would encounter if they would be first diluted in saline 
solution to 1000ppm of Fe and then administrated to the serum to 300 ppm of Fe. The 
same dilution but with saline worked as the control (Figure 33). This is the most probable 
outcome that we would find in vivo as it is the most safer and ergo frequent administration 
strategy [65]. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 As shown in Figure 33, practically all iron from Cosmofer®, Ferinject® and 
Monofer® passed through the filters, although Venofer® showed the highest percentage of 
trapped iron (3.54 ± 1.80 %) as it happened in Figure 32. Furthermore, the iron from 
Venofer® trapped in these conditions was lower, because since the saline adjusts the 
Figure 33 - % of filtrated iron of the 4 IV irons after 1000kDa filtration by centrifugation, 
mimicking the administration of diluted IV iron to serum. The red bars are the control. 
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osmolarity of the suspension to match the blood plasma one (280-300 mOs/kg), we would 
expect that 300ppm of undiluted Venofer®, typically with higher osmolarity [55], would 
interact more easily with the serum components, in the same period of time.  
 The overall results confirm Venofer® as the one with the greatest adherence to 
serum components, although 300 ppm of Fe would never be encountered in vivo after an 
administration of Venofer®, which proves the importance of the maximum dose of 
Venofer® being as low as 200 mg and the concentration of iron never exceeding 62.5 ppm 
(considering the volume of distribution of 3.2 L [57]). Nevertheless, the agglomeration 
seen at 50 ppm of Fe in the presence of calcium and phosphate confirms that Venofer® has 
a high affinity for serum components even in lower iron concentrations, which constitutes 
a concern since at both maximum and low doses, we can assume that Venofer® adsorbs 
unwanted serum molecules while in circulation till it is completely removed from the 
blood. Thus, it is conceivable that this unspecific binding to serum electrolytes and 
possibly to unspecific proteins might be related to some of the side effects related to 
Venofer®, seen in concentrations below the maximum ones after administration of the 
maximum dose [85]. In contrast, Monofer® agglomerated in concentrations below the 
maximum one permitted 533.3 ppm (considering the maximum dose of 1600 mg and its 
distribution volume of 3 L [69]) which indicate that this material may not be the safest and 
more reliable IV iron preparation [27]. 
The zeta potential was measured to all IV irons with 1000 ppm of iron in water at 
pH ~ 7.4 (Figure 33) to try to relate its surface charge to the adherence of the nanoparticles 
to serum molecules. 
 
 
 
 
 
 
 
 
 
 
Figure 33 - Zeta Potential obtained for the four IV materials at 1000ppm of iron and pH 7.4 (blue bars). The zeta 
potential found in literature at similar pH is in red bars.  
Venofer Cosmofer Monofer Ferinject 
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The 1000 ppm concentration is the lowest that we would find entering the blood 
stream if the IV iron (Venofer®) was diluted in 0.9% NaCl immediately before 
administration [62]. In these conditions, all the materials have a negative zeta potential and 
therefore a negative surface charge which agrees with the data in the literature. Venofer® 
and Monofer® have the most negative charge due to their large negative zeta potential. 
This might explain why these had the highest indices of agglomeration with serum, 
because there is evidence that highly charged nanoparticles have a much higher 
opsonization (coating by serum proteins) rate than neutral or slightly charged nanoparticles 
[121]. Although opsonization is required to transport the nanoparticles safely and directly 
to macrophages, this coating can also be carried out by other than the requested proteins 
when the conditions are suitable. 
 Ferinject® is widely reported to induce hypophosphatemia more frequently than 
the others, due to its reported natural positive charge in acidic pH [50]. But at 
physiological pH it showed a negative zeta potential which means that, once it is well 
dispersed in the blood, an electrostatic interaction with negatively charged phosphate might 
be weak. However, when we diluted Ferinject® to 1000 ppm and 500 ppm of Fe, in acidic 
pH, the measured zeta potential confirmed the positive charge, in both concentrations with 
less errors at 500 ppm: pH = 4.71 and zeta potential = + 6.69 ± 0.97 (Figure 34). So, we 
can assume that Ferinject® has a positive surface charge for a short term in the blood 
immediately after the administration, during which it can adhere electrostatically to 
phosphate until the pH is normalized to physiological values. This may also explain why 
some reports point towards a more transient hypophosphatemia [27, 65]. Plus, maybe with 
increasing doses of Ferinject®, the enhanced positive charge might exacerbate the severity 
of the hypophosphatemia. 
 
5.4 Lysosomal dissolution assay 
 After studying IV iron materials in serum conditions, we analysed them in an 
intracellular environment by performing a lysosomal dissolution assay. In this assay, we 
mimicked the conditions that nanoparticles would face after being internalized by the 
macrophages into the endolysosomes by subjecting the nanoparticles to pH, temperature 
and chelation conditions of the lysosome to stimulate the actual dissolution of the 
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nanoparticles by studying the variation of soluble iron with increasing time and, 
subsequently, determine the relative lability between IV iron products. The first thing 
needed to do was to find out the best pH, chelating agent and concentration of iron to allow 
a more efficacious dissolution and to realize which time points are the most representative 
of the evolution of the iron solubilisation. The best pHs to test are pH 4.5, 5.0 and 5.5 
because the pH 4.5 and 5.0 are thought to be the border values of the range within which 
the common physiological value of lyosomal pH is maintained, that is 4.7 [122]. pH 5.5 
occurs for late endosomes when they are acidified after common cellular iron uptake [2]. 
The most suitable chelates are citrate, isocitrate and phosphate because they are considered 
to enhance solubilisation of iron in lysosomal conditions [123, 124]. The concentrations 
selected were 0.1, 0.5 and 1 mM of iron because they allow the detection and 
quantification of iron concentrations by the ICP-OES in conditions where small 
percentages of that concentration of iron are dissolved between two time-points. 
 The kinetics of the evolution iron are not significant for the purpose of selecting the 
best pH, concentration of iron and chelating agent because we want the conditions that 
originate the most percentage of soluble iron to get sufficiently different percentages 
between the four IV irons. With these differences, we can assess their relative lability and 
study the dissolution kinetics at the same time. 
The first experiment selected the iron concentration that yielded the higher 
percentage of soluble iron after 7 days with pH 5.0 and 10 mM of citrate (Figures 34 and 
35). 
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Figure 35 – Distribution of the precipitated, nanoparticulated and soluble 
iron fraction of Venofer, present in different iron concentrations, at pH 5.0 
and 10mM of citrate, after 7 days of dissolution. 
Figure 34 - Variation of the concentration of soluble iron in three different iron concentration conditions 
at pH 5.0 and 10mM of citrate, during the first 7 days of dissolution, for Venofer. The variation until 6h 
was expanded. 
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 0.1 mM of Fe was preferred because although it presented the slowest release of 
iron and the lowest iron concentration after seven days, it showed a much higher 
percentage of iron in the soluble form than the other two. 
Then, we selected the pH that yielded the higher percentage of soluble iron after 7 
days with iron concentration of 0.1mM and 10mM of citrate (Figure 36 and 37). 
 
 
 
 
 
 
  
 
 
 
 
 
 
       
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36 - Variation of the concentration of soluble iron in three different iron pH conditions at 
0.1mM of Fe and 10mM of citrate, during the first 7 days of dissolution, for Venofer. The 
variation until 6h was expanded. 
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 The pH 4.5 was preferred because not only it presented the fastest release of iron 
but after 7 days the concentration and percentage soluble iron was bigger than the other 
two.  
Finally, we selected the chelating agent that yielded more percentage of soluble 
iron after 7 days with iron concentration of 0.1mM and pH 4.5 (Figure 38 and 39). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 37 – Distribution of the precipitated, nanoparticulated and 
soluble iron fraction of Venofer, present in different pH conditions, at 
0.1mM of Fe and 10mM of citrate, after 7 days of dissolution. 
Figure 38 - Variation of the concentration of soluble iron in three different chelating agent buffers, at 
0.1mM of Fe and pH 4.5, during the first 7 days of dissolution, for Venofer. The variation until 6h was 
expanded. 
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 Although citrate presented the slowest release of iron and the lowest iron 
concentration, after seven days, the percentage of soluble iron was quite similar to 
isocitrate. Therefore, as citrate is much more easily available and cheaper than isocitrate, it 
was chosen due to its convenience. 
 Although we have selected the conditions that produce the highest percentage of 
iron after 7 days of dissolution and, at the same time, correspond to physiological 
conditions in the lysosome, the percentage is not high enough (< ~20%) to obtain 
reproducible percentages to all four IV materials. So, a more acidic dissolution was carried 
out at pH 2.5, 0.1 mM of iron and 10 mM of citric acid (used as the chelating agent and 
also to adjust initially the pH) to see if we could increase the dissolution performance 
(Figure 40 and 41). This time, two replicates were prepared independently (as well as the 
blanks) and the only shared step was the incubation of all the vessels in a water bath in the 
same conditions of temperature and stirring during the seven days of the experiment. 
 
 
  
Figure 39 – Distribution of the precipitated, nanoparticulated and 
soluble iron fraction of Venofer, present in different chelating agents, 
at 0.1mM of Fe and pH 4.5, after 7 days of dissolution. 
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Figure 41 – Distribution of the precipitated, nanoparticulated and soluble 
iron fraction present in two different pH conditions at 0.1mM of Fe and 
10mM of citrate/citric acid, during the first 7 days of dissolution. 
Figure 40 - Variation of the concentration of soluble iron in two pH conditions, at 0.1mM of Fe and 10mM of 
citrate/citric acid, during the first 7 days of dissolution, for Venofer. The variation until 4h was expanded. 
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 The pH remained stable around 2.50 during the incubation. At this pH, the 
dissolution was much faster and greater than at the conditions with pH 4.5, giving 98.83% 
of soluble iron after seven days. So, the citric acid at pH 2.50 and the iron concentration of 
0.1 mM proved to be the best experimental conditions for the dissolution of iron for a 
period of seven days. However, it is unknown whether the lower pH or the chelating effect 
is favouring the dissolution of iron, because the pH 2.50 is slightly below the first pka of 
citric acid (pka = 3.128) meaning that most of the citric acid is fully protonated giving a 
weaker chelating effect. Therefore, in a further experiment, the IV iron materials were 
mixed in water at pH 2.5 without chelating agent (HCl was the pH adjuster) to allow the 
pH effect on the dissolution of iron (Figure 42 and 43). Two replicates were also prepared 
independently (as well as the blanks) and the only shared step was the incubation of all the 
vessels in a water bath in the same conditions of temperature and stirring during the seven 
days of the experiment. As we got more than 50% of soluble iron after 24h in the citric 
acid dissolution, the dissolution in water was only conducted during 24h. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 42 - Variation of the concentration of soluble iron with and without chelating agent, at 
0.1mM of Fe and pH 2.5, during the first 24h of dissolution, for Venofer. The variation until 4h 
was expanded. 
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The pH was thoroughly monitored in each time-point and as HCl does not behave 
like a buffer, the pH slightly changed during the dissolution, so additions of NaOH to the 
vessels were made in two different occasions (between 0 min and 24h) due to a slight 
decrease of the pH. It remained stable around 2.50 after 24h of incubation. With just the 
pH effect, the dissolution was much slower than at the conditions with citric acid at pH 
2.50, giving an average percentage of 33.36 ± 4.238 % of soluble iron after seven days. It 
proves that at pH 2.50, the citric acid has a substantial buffer effect and also that the 98% 
of soluble iron observed with the citric acid at pH 2.50, after 7 days, was mainly due to the 
chelating effect. This being said, we can decrease the time of the experiment and 
guarantee, at the same time, an appropriate soluble iron percentage. So, the experimental 
conditions of 0.1mM Fe, 10mM citric acid at pH 2.50 and 24h dissolution period prove to 
be the best ones for a reproducible dissolution to an extent that allowed a good comparison 
of the iron lability between all the materials.  
 With these conditions selected, this method was applied to all the IV irons (Figure 
44, 45 and 46). 
 
  
Figure 43 – Distribution of the precipitated, nanoparticulated and soluble 
iron fraction present with and without chelating agent, at 0.1mM of Fe and 
pH 2.5, during the first 24h of dissolution. 
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Figure 44 - Variation of the concentration of soluble iron for the four IV materials during 24h, at an iron concentration 
of 0.1mM, pH 2.5 and 10mM of citric acid. The variation until 4h was expanded. The dashed coloured lines lines are 
the respective blanks. 
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Figure 46 – Distribution of the precipitated, nanoparticulated and soluble iron fraction present in the four 
materials, after 24h days of dissolution, at an iron concentration of 0.1mM, pH 2.5 and 10mM of citric acid. 
Figure 45 - Variation of the concentration of soluble iron in the four IV materials during 24h, at an iron concentration of 
0.1mM, pH 2.5 and 10mM of citric acid.  The linear trend was added top each graph. 
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 When we compare the four IV iron materials in terms of kinetics, Cosmofer®, 
Ferinject® and Monofer® resemble a linear trend line during all the experiment whereas 
Venofer® show a softening in the increase of soluble iron with time proved by the highest 
deviation of the linear trend line (lowest R, 0.9455). Nevertheless, Venofer® shows a 
higher rate of dissolution during 24h giving a percentage of 84.58% of soluble iron in the 
end, and also a higher percentage of soluble iron after 4h than the percentages of soluble 
iron in the other three IV iron materials at 24h. Thus, the dissolution of iron sucrose was 
fast enough to dissolve most of the iron which explains the slight decrease in the 
dissolution rate after the 8h. In Cosmofer®, Monofer® and Ferinject®, the concentration 
of soluble iron increased with time in a linear trend showing that the degradation of these 
nanoparticles and consequent solubilisation of iron is not saturable till 24h of dissolution. 
Just 21.07% (Ferinject®), 27.8% (Monofer®) and 32.79% (Cosmofer®) of iron was 
soluble after 24h, so the dissolution was not fast enough to dissolve most of the iron during 
this time, giving that in the experimental conditions of 0.1mM Fe, pH 2.5 and 10mM of 
citric acid, there is enough nanoparticulated iron during 24h to drive the dissolution of 
Cosmofer®, Ferinject® and Monofer® in a constant rate similar to a 0 order kinetics.  
 This data supports the notion of different iron core-carbohydrate shell strengths and 
different particle size as the driving forces to the lability of an IV iron material, as these 
ones differ in such aspects. Venofer® is the most labile and has the smallest nanoparticles 
(~8.3nm) while Ferinject® is the least labile and the one with the biggest particle size 
(~23.1nm). The bigger the particle, the lower is the surface area/volume ratio and the more 
compact and robust is the iron core ergo the material is less likely to release iron. 
Monofer® nanoparticles are smaller than Cosmofer® ones but they are less labile. The 
explanation might reside in the type of interaction between the iron core and the dextran-
like carbohydrate shell, which both materials share. But while Cosmofer® has a shell of 
high length branched polymers surrounding the core, Monofer® has pure linear oligomers 
arranged in a matrix-like structure with interchanging iron molecules in a strongly bound 
structure that enables a controlled and slow release of bioavailable iron. This unique robust 
structure is remarkably core protective because Monofer® is just slightly more labile than 
Ferinject® and has less than half of the size of it, which makes us conclude that changing 
the carbohydrate structure is more relevant to alter the lability of these compounds. 
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 As mentioned before, the dissolution profile also depends on the type mineral phase 
and the presence of amorphous iron increases the dissolution of a iron oxyhydroxide [125]. 
The 2-line ferryhidrite mineral phase has a higher surface area (225 m
2
/g) than akaganeite 
(77.8 m
2
/g) [119] and a higher disordered structure and amorphousness [118]. So, the 
ferrihydrite crystal structure of Venofer® might have enhanced the dissolution because 
more weakly  bound iron was exposed to the protons in the solution. By the XRD data, we 
can relate the lowest dissolution performance belonging to Ferinject® with its akaganeite 
crystallinity and with the certain level of amorphousness observed in Cosmofer® and 
Monofer®. The lowest lability found in Ferinject® and Monofer® proves the high stability 
of the third generation materials and their capacity to greatly decrease the incidence of 
lability-driven anaphylactoid reactions, contrasting with the second generation IV irons 
such as Venofer®. 
 A pH driven dissolution (pH 2.5 and 0.1mM of Fe) was carried out to see if the 
dissolution behaviour resembled the chelating agent + pH-driven dissolution (Figure 47 
and 48). 
 
Figure 47 – Chelating agent+ pH-driven dissolution (blue lines) and the pH-driven dissolution (red lines) of the four IV 
materials during 24h, at an iron concentration of 0.1mM. The variation until 4h was expanded. 
0,0
0,2
0,4
0,6
0,8
1,0
1,2
1,4
0 1 2 3 4
[F
e]
 p
p
m
 
time (h) 
Venofer pH 2.5 + CA
Monofer pH 2.5 + CA
Ferinject pH 2.5 + CA
Cosmofer pH 2.5 + CA
venofer pH 2.5
Ferinject pH 2.5
Cosmofer pH 2.5
Monofer pH 2.5
85 
 
12,1 
3,3 3,9 2,9 
18,4 
10,0 11,8 
5,5 
69,5 
86,7 84,2 91,5 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Venofer Cosmofer Monofer Ferinject
Ir
o
n
 p
h
as
e
 d
is
tr
ib
u
ti
o
n
 
% nanop.
% precip.
% sol.
 
If we compare the acidic dissolutions of the four IV materials, Cosmofer®, 
Ferinject® and Monofer® had a similar behaviour during the dissolution as they 
showed a poor increase of soluble iron with the tendency to stabilize with time in a way 
that in the end, these three materials shared similar concentration and percentages of 
iron. Venofer® clearly diverges from the others by showing a faster and higher increase 
of soluble iron with 12.1% of iron in the soluble form after 24h, even though the 
progression is quite unclear till 6h due to big standard deviations. The pH driven 
dissolution was not suitable to study and compare the behaviour of the four IV iron 
materials because the percentages of soluble iron found in Cosmofer®, Ferinject® and 
Monofer® do not diverge significantly enough to conclude about their relative lability. 
So, the addition of citric acid to an acidic environment still provides a more accurate 
dissolution with more distinguishable kinetic behaviours and, thereby, a more reliable 
approach to conclude about the relative labilities, also in a more physiological scenario.  
To possibly obtain the same dissolution performance as the pH+chelating agent-
driven dissolution but maintaining a more physiological scenario, we tried to optimize 
the assay by increasing the concentration of chelating agent. Two dissolutions of 
Venofer® were made, both at pH 4.5, 0.1mM of Fe but with 20mM and 50mM of 
Figure 48 – Distribution of the precipitated, nanoparticulated and soluble iron fraction present in the four 
materials, after 24h days of pH-driven dissolution, at an iron concentration of 0.1mM and pH 2.5  
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citrate. 20mM was assumed to be the sum of the concentrations of all the organic acids 
in the lysosome if we consider 10mM of citrate, whereas 50mM is the concentration of 
citrate in the lysosomes of the rubber tree [113] (Figure 49 and 50). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 49 - Variation of the concentration of soluble iron in Venofer during 24h, at an iron concentration of 
0.1mM, pH 2.5 and 10mM of citric acid. The variation until 4h was expanded. 
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 During all the incubation period, the dissolution rate with 10mM of citrate was 
much lower compared to the other two samples. Until 8h, the dissolution with 20 mM of 
citrate increased the concentration of soluble iron at a similar rate as the one with 50 mM. 
However, between 8h and 24h, the increase of soluble iron was just 0.18 ppm for the 20 
mM solution whereas in the 50 mM of citrate solution the soluble iron continued to rise at 
the same pace, giving an arise of 0.62 ppm. This difference makes the concentration of 50 
mM of citrate the most efficient in releasing soluble iron from the nanoparticles core, with 
25.2% of soluble iron after 24h. Ultimately, and based on what was mentioned before, we 
can assume that with 50 mM of citrate we have the most similar representation of the real 
dissolution kinetics of 0.1 mM of nanoparticulated iron in the macrophage lysosome, but, 
although the increase of the concentration of chelating agent increases the dissolution rate, 
at this best physiological conditions, the percentage of soluble iron is far from the extent 
obtained after the same period of time at pH 2.5 and 10 mM of citric acid (84.6%), which 
makes the intracellular mimicking conditions the less suitable to be applied to study the 
relative labilities between the four IV iron products.  
 
Figure 50 – Percentages of the precipitated, nanoparticulated and soluble iron 
fraction of Venofer, present in different citrate concentrations conditions, at 0.1mM 
of Fe pH 4.5, after 24h of dissolution. 
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5.5 Voltammetric analysis of ferric and ferrous content in 
Venofer®. 
 Voltammetry measurements are important not only to determine the presence of 
ferrous iron for its own toxicity, but also to relate its presence to the dissolution 
performance, because the ionic radius of Fe
2+
 (0.74 A) is larger than that of Fe
3+
 (0.64 A), 
so that the Fe
2+
-O bond will be longer and weaker than the Fe
3+
-O bond. Because the 
dissolution of iron oxides involves the breakdown of Fe-O bonds, the dissolution of IV 
iron material with ferrous content is expected to be faster [125]. 
As the concentrations recommended in method V-127 were as low as 20 ppm, we 
used  differential pulse polarography as it is quite sensitive due to the detection limit being 
as 10
-7 
to 10
-9 
M and because it is less sensitive to changes in the experimental conditions 
which leads to better precision and accuracy [106]. 
 The first scan of Venofer® showed the presence of both ferric and ferrous iron, 
represented by the presence of the respective peaks at around -0.9 V and -1.4 V (Figure 51 
and Table 14). However, the figure and the table shows a Fe
2+
 peak almost 8 times bigger 
(in terms of current) than the ferric one, which is in contradiction with the ferric hydroxide 
form present in the iron core. So, two reasons might explain this: somehow there is 
considerable amount of ferrous iron in the stock solution of Venofer®, or its peak is 
enhanced by the permanence of ferrous iron in the vicinity of the working electrode 
(boundary layer) after being formed by the reduction from the original ferric iron.  
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Iron specie Potential (V) Current (nA) 
Fe
3+ 
-0.892 ± 0.020 -37.66 ± 0.295 
Fe
2+ 
-1.434 ± 0.006 -296.9 ± 0.228 
 
  
 As the iron core is ferric in nature and as the presence of ferrous iron in a IV iron 
stock solution has serious safety implications, we tested the method with ferric chloride 
and ferrous sulphate to determine the origin of the ferrous specie and, subsequently, if the 
method works (Figure 52 and 53). The results showed one peak when FeSO4 was added, 
as expected, but it showed two peaks about the same size when FeCl3 was added.  
Figure 51 - Linear voltammogram of Venofer when reducing potentials are applied. The first and second peaks correspond 
to ferric and ferrous species, respectively. U is the potential applied (voltage) and I is the resulting current (amperes). 
Table 14 - Current peak average (nA) and the correspondent average potential (V) 
for ferrous and ferric species.  
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These results point more towards the formation of the ferrous boundary layer as the 
explanation of the ferrous content in the Venofer® voltammogram. In fact, although the 
Figure 52 - Linear voltammogram of ferrous sulphate when reducing potentials are applied. The only peak corresponds 
to the ferrous specie. U is the potential applied (voltage) and I is the resulting current (amperes). 
Figure 53 - Linear voltammogram of ferric chloride when reducing potentials are applied. The first and second peaks 
correspond to the ferric and ferrous specie, respectively. U is the voltage applied (voltage) and I is the resulting current 
(amperes). 
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dropping mercury has the ability to easily renew the surface of the working electrode by 
producing a new drop, the electrode is static and, thereby, the mass diffusion between the 
analytes at the surface of the electrode and in the solution is not carried out. Therefore, the 
ferrous iron produced in the electrode from the reduction of the ferric iron is not expelled 
to the bulk solution and it is reduced to Fe
0
 at the electrode compromising the detection 
and quantification of the possible ferrous specie originally in the stock. 
 Later on, the DME was substituted by a RDE. This solid electrode mechanically 
stirs the solution in the vicinity of the electrode expelling the reduced products, which 
avoids the formation of the ferrous layer and still obtains the limiting current from 
potential pulses. This hydrodynamic voltammetry shows voltammograms identical to those 
for polarography, except for the lack of current oscillations from the growth of the mercury 
drops [106]. Although RDE is reported to be less sensitive than the DME, it is sensible 
enough to provide accurate quantifications at the concentrations used in this experiment 
because it can restore the sensitivity limit to that of the nearly ideal situation by 
overcoming the interference from electrode surface adherence or supporting electrolyte 
reactions to the generation of current, quite common in DME [126].  
 When we scanned Venofer® using the same concentrations and parameters, just 
one small ferric peak (around -0.550V) was shown although quite smaller than the ones 
normally obtained with the DME (Figure 54 and Table 15). 
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Iron species Potential (V) Current (uA) 
Fe
3+ 
-0.548 ± 0.006 -1.333 ± 0.157 
 
 
 
Figure 54 - Linear voltammogram of Venofer (20ppm of Fe) with the RDE as the working electrode, when reducing 
potentials were applied. The peak was expanded and corresponds to the ferric specie. 
Table 15 - Current peak average (uA) and the correspondent average potential (V) 
for the ferric specie.  
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 If we consider the results from Figure 54 as correct, Venofer® seems to have very 
low soluble iron content in the stock solution, and it is all in the form of ferric iron. So, the 
side effects associated with Venofer® are most likely not due to the presence of ferrous 
iron in the stock solution, and the dissolution performance of Venofer® was not influenced 
by the presence of the weaker Fe
2+
-O bounds.  
 The peak is, however, too small, so, to increase the reproducibility, we should have 
made the bulk solution richer in soluble iron to get a more evident spectrum and a realistic 
determination of the redox state of the iron. To do so, we could have decreased the pH or 
used citric acid in the electrolyte solution, based on the success of these parameters in 
producing soluble iron. We could have also increased the acetate concentration in the 
electrolytes solution because it has been proved to dissolve iron hydroxide nanoparticles 
[97], which is evident in the results of four consecutive voltammetry measurements 
effectuated to Venofer® in RDE conditions. The current peak height increased from -
1.333uA A in the first measurement, to -1.417uA in the fourth one, which is an accurate 
manifestation of the ferric core dissolution and the consequent increase of soluble iron in 
the solution. This behaviour makes linear voltammetry a potential adequate method to 
follow the nanoparticle dissolution through time, which would become a novel and a more 
accurate and progressive way to assess and compare the lability of each material. 
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Conclusion 
 The high iron lability and the related anaphylactoid type reactions of Venofer® 
have been previously reported, and those concerns were corroborated by the dissolution 
assays. in the current project, which showed that Venofer®, since it has a small particle 
size, is by far the most labile material, confirming the need for the current practice of 
administrating it in small doses and as a slow push or infusion, although it can deliver iron 
faster to Tf, because greater doses or faster rates of administration are associated with 
serious anaphylactoid type reactions. Moreover, the strong evidence of agglomeration in 
the calcium/phosphate solution and in FBS showed that Venofer® appears to adsorbe 
serum compounds indicating that the sucrose contains a weak protection of the iron core, 
as this affinity is most likely due to the interaction between the iron core and electrolytes 
and not to the negative surface charge. This has serious implications regarding the safety of 
Venofer®, as it shows that not only its lability results from the small particle size but also 
to the weakness of the coating protection. 
 The safety concerns of Cosmofer® are mostly due to its dextran-induced 
anaphylaxis, however, Cosmofer® presented a degree of core amorphousness, which could 
have been the cause of the evidences of agglomeration in the presence of calcium and 
phosphate and, along with the fact that Cosmofer® was the second highest labile 
compound, it compromises the supposed robustness of the dextran coating, and rises 
questions about the adequacy of the high dosage strategy allowed. 
 Ferinject® presented the lowest lability profile as it has the biggest particle size. 
Furthermore, it was the only one to show a high level of crystallinity resembling to 
akaganeite, which demonstrates that not only the particle size and the strength of the 
carbohydrate shell-core bound are driving forces to the lability and stability of a 
nanoparticle and, thereby, to the safety of an IV iron material. However, its safety is deeply 
compromised due to the reports of hypophosphatemia. Although not fully understood, the 
surface positive charge obtained by the zeta potential might favour a high affinity to the 
free phosphate and diminish its blood levels once the material is administrated. 
 Monofer® showed a very low iron lability making it a robust material with a 
controlled and slow release of bioavailable iron while in serum, which might explain the 
reports of minimal free iron release.  Nevertheless, it joins a robust structure to a small 
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particle size, explaining why it is rapidly uptaken by the macrophages, as it is characteristic 
of smaller nanoparticles, avoiding the potential harm associated with long-term circulation 
times. But, because of its robustness they will donate the iron slowly when being processed 
by the lysosome. So, these two properties together confer a high level of safety both in 
circulation and in intracellular environments, which might explain why Monofer® is the 
safest IV iron available and also why it has a high and fast dosage allowance with the 
chance of repleting the iron stores in one dose. However, the current paradigm that 
Monofer® may be the first-line therapy with no safety concerns should be reconsidered as 
its mineral phase showed high levels of amorphousness which due to its likelihood to 
facilitate electrostatic interactions and ligand exchange bounds, could have explained the 
evidences of agglomeration in the presence of serum. Therefore, there is still a need for a 
prospective work to perform a more thorough characterization of its affinity to serum 
molecules and to better understand the implications of these findings in the actual in vivo 
scenario. 
 Overall, Venofer®, Cosmofer®, Ferinject® and Monofer® showed different 
physicochemical profiles regarding the level of crystallinity of the core, the dissolution 
performance and consequent lability, and the agglomeration behaviour in the presence of 
serum or calcium/phosphate solutions. These different physicochemical profiles 
individualize each IV iron and strikingly demonstrates that a high crystallinity mineral 
phase, a negative surface charge and a strong and protective non-sucrose polymer 
carbohydrate shell are the key factors for a stable, safe and ergo, efficient IV iron material  
for the treatment of anaemia. 
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Future Work 
 To accurately assess the nanoparticle agglomeration in the presence of phosphate, 
we should do elemental analysis by ICP-OES of a mixture containing each IV iron material 
and a calcium and phosphate solution and link it with the particle sizing results. To do that, 
we should quantify the phosphate that was adsorbed to the nanoparticles and quantify the 
agglomerated iron to then relate both of them and get a more quantitative and, thereby, 
sensible agglomeration scenario. Equivalent serum assays should also be performed to 
assess the undesirable dissolution of the IV iron preparations under serum conditions that 
could lead to NTBI. The IV iron preparations could be exposed to citrate, albumin and 
acetate, instead of calcium and phosphate, as these would mimic the ideal conditions for 
the formation of NTBI.  
 A Linear voltammetry method to study the dissolution profile of an IV iron 
material should be developed because it will enable the direct assessment of the variation 
of soluble iron in real time during the dissolution and it will not be associated with the 
errors always associated in the preparation (i.e. pipetting, disrupted filter) and analysis (lab 
material contamination) of supernatant and ultrafiltrated iron samples when elemental 
analysis by ICP-OES is being conducted. Another, more relevant mode would be the 
macrophage stimulation with IV iron followed by ferritin and total protein quantification in 
several time-points. With the variation of ferritin concentration with time, this in vitro 
assay should represent accurately the in vivo dissolution profile and kinetics of each IV 
iron.  
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Appendix 
 
XRD spectrums of Dextran 1000kDa polymers, Dextran 5000kDa and sucrose: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 55 - XRD characterization of Dextran 1000kDa. 
Figure 56 - XRD characterization of Dextran 5000kDa. 
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 The statistic graphs of the particle sizing obtained for Venofer®, Cosmofer® 
Ferinject® and Monofer® diluted in water (50mg/mL of Fe): 
 
 
Figure 58 - Statistics graph of the size distribution by volume of Venofer® 50mg/L  of iron. Total of nine 
measurements. 
Figure 57 - XRD characterization of Dextran 5000kDa. 
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Figure 60 - Statistics graph of the size distribution by volume of Ferinject® 50mg/L of iron. Total of nine 
measurements. 
Figure 61 - Statistics graph of the size distribution by volume of Monofer® 50mg/L of iron. Total of nine 
measurements. 
Figure 59 - Statistics graph of the size distribution by volume of Cosmofer® 50mg/L of iron. Total of nine 
measurements. 
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 The graphs of the Size distribution by volume obtained for Venofer®, Cosmofer® 
Ferinject® and Monofer® diluted in the calcium and phosphate solution (50mg/mL of Fe): 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 62 - Size distribution by volume of Venofer® diluted with the calcium and phosphate solution (50mg/L of 
iron). Total of nine measurements. 
Figure 63 - Size distribution by volume of Cosmofer® diluted with the calcium and phosphate solution (50mg/L of 
iron). Total of nine measurements. 
Figure 64 - Size distribution by volume of Ferinject® diluted with the calcium and phosphate solution (50mg/L of 
iron). Total of nine measurements. 
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 The statistic graphs of the zeta potential obtained for Venofer®, Cosmofer® 
Ferinject® and Monofer® (1000ppm of Fe) at pH ~7.35: 
 
 
 
Figure 66 - Statistics graph of the zeta potential distribution by Intensity of Venofer® 1000ppm of iron. Total of 
three measurements. 
Figure 65 - Size distribution by volume of Monofer® diluted with the calcium and phosphate solution (50mg/L of 
iron). Total of nine measurements. 
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Figure 67 - Statistics graph of the zeta potential distribution by Intensity of Cosmofer® 1000ppm of iron. Total of 
three measurements. 
Figure 68 - Statistics graph of the zeta potential distribution by Intensity of Ferinject® 1000ppm of iron. Total of 
three measurements. 
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 The statistic graph of the zeta potential obtained for Ferinject® (500ppm of Fe) 
without pH adjustment (pH = 4.71): 
 
 
Figure 69 - Statistics graph of the zeta potential distribution by Intensity of Monofer® 1000ppm of iron. Total of 
three measurements. 
Figure 70 - Statistics graph of the zeta potential distribution by Intensity of Ferinject® 500ppm of iron at pH 
4.71. Total of three measurements. 
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 This is a typical calibration graph obtained in one batch of an ICP elemental 
analysis of iron. The three calibration curves resulted from the measurement of 9 iron 
standards before starting the measurement of the samples, in between, and after measuring 
all the samples. 
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Figure 71 – Three calibration curves obtained during one batch of an ICP elemental analysis of iron.  
